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Abstract 
 
Stephen Gee 
The role of Yes-associated protein (YAP) in vertebrate development 
(Under the direction of Sharon L. Milgram) 
 
Yes-associated protein 65 (YAP) contains multiple protein-protein interaction 
domains and functions as both a transcriptional co-activator and as a scaffolding protein 
within the cytoplasm or nucleus. Given that YAP binds to so many proteins that are critical 
for proper embryonic development and that this factor functions as a transcriptional co-
activator, YAP likely plays an important role during early embryonic development. 
Given that YAP knockout mice struggled to progress normally through early 
development, in part because of nutritional deficiencies, we sought to better characterize a 
role for YAP during this time period by using embryos that develop externally: Xenopus 
laevis and Danio rerio. YAP morpholino (MO)-mediated loss-of-function resulted in a delay 
of mesoderm induction and severely impaired A-P axis elongation, phenotypes that were 
similar to YAP-/- mice. YAP gain-of-function experiments in Xenopus laevis expanded the 
progenitor populations in the neural plate and neural plate border zone, while concomitantly 
inhibiting differentiation markers for the neural crest, preplacodal ectoderm, hatching gland, 
epidermis, and somitic muscle. 
Regulation of gene expression is critically important in development and improper 
regulation of gene expression can lead to a variety of developmental defects, such as loss of 
 iv 
conceptus, birth defects, and cancer. I found that yap expression is controlled by a TATA-
less promoter, which includes a GC box where Sp1 binds and regulates yap transcription. I 
also found that adrenomedullin, a multifunctional peptide hormone known to act as a 
vasodilator, angiogenic factor, regulator of placental development, and tumor growth 
promoter, is a newly identified, putative target of YAP.  
These studies demonstrate that YAP is involved in the process of cell differentiation 
and the lack or overabundance of YAP protein disrupts the developmental time line of 
vertebrates with grievous consequences. Understanding the mechanistic details of these 
effects involve delineating the transcriptional control of YAP and its target genes. In the 
future, elucidating the linkage between YAP, the nuclear architecture, and transcriptional 
regulation will bolster our understanding of cell differentiation. 
 v 
Acknowledgements 
 
During a graduate student’s pursuit to graduation, they receive many forms of advice, 
both personal and professional, from a multitude of people with varied backgrounds. I would 
like to use this space to acknowledge those for whom without whom this document would 
have been completed. I am eternally grateful and indebted to those scientists before me, who 
persisted, sacrificed, and persued their less traveled investigations even when others thought 
the ideas imprudent.  
My parents, Roger and Nita Gee, provided a loving, supportive family in which to 
learn and grow. Without their continued love and support, this work would not exist. I am 
also grateful to the positive mentors who encouraged me throughout my early education, 
including my Seventh Grade Biology Teacher, Gail Sumwalt, my Advanced Placement High 
School Biology Teacher, Paula Alderfer, my High School Band Director, Benny Ferguson, 
and my High School Cross Country and Track coach, Bob Jenkins.  
There are many people to thank for their contributions to this work, but I would like 
to start by thanking Sharon L. Milgram for giving me the opportunity to complete this work 
in her lab, for her invaluable advice and guidance, and for her continued positive 
reenforcement. This work could not have been completed without the support, mentoring, 
patience, and scientific guidance of Sally A. Moody. I thank Jeremy Teed and Robin Shah 
for their persistant hard work in collecting portions of the described work, which contributed 
to their UNC Honor’s Theses. I also thank the varied contributions, both personal and 
 vi 
scientific, of the following: Elizabeth M. Morin-Kensicki, Frank L. Conlon, Vytas A. 
Bankaitis, Patrick J. Brennwald, Kenneth L. Kramer, Michael Howell, Anthony P. Barnes, 
Caleb A. Hodson, William R. Thelin, Chris Showell, Daniel D. Brown, Augustin G. 
Caballero, Brian Boone, Gaby Haddock, Blake Carrington, Bo Yan, Karen M. Neilson, 
David Phillibert, and Lindsey Buckingham. I thank my wife, Dawn Kashelle Lockman, and 
my daughter, Kailey Arden Gee for their love, encouragement, and continued support. 
Finally, I would like to dedicate this dissertation to those important to me, whom 
were unable to see the completion of this work: Ruth Stroud Gee (grandmother), Mary Sue 
Crump (grandmother), and Vonnie Roberts (grandfather-in-law). 
 vii 
Table of Contents 
 
List of Tables…………………………………………………………………………..……..ix 
 
List of Figures…………………………………………………………………….………..….x 
 
List of Abbreviations………………………………………………………………......…....xiii 
 
List of Symbols………………………………………………………………………...……xvi 
 
Chapter I – Background……………………………………………………………………..1 
  
  Yes-associated protein (YAP)……………………………………………...….2 
  
  Transcriptional co-activator with PDZ-binding motif  (TAZ)……...………..10 
   
Chapter II –YAP expands neural progenitors and regulates pax3 expression  
in the neural plate border zone…………………………………………………………….24 
  
  Introduction…………………………………………………………………..25 
 
  Materials and Methods……………………………………………………….27 
 
  Results………………………………………………………………………..36 
 
  Discussion……………………………………………………………...….....98 
 
 
Chapter III – Transcriptional control of YAP..................................................................107 
 
  Introduction…………………………………………………………………108 
 
  Materials and Methods……………………………………………………...111 
 
Results………………………………………………………………………114 
 
Discussion…………………………………………………………………..134 
 
Chapter IV – Identification of putative YAP transcriptional target genes…………....140 
 
 viii 
Introduction…………………………………………………………………141 
 
  Materials and Methods…………………………………………………...…141 
  
Results and Discussion……………………………………………………..148 
 
Chapter V – Summary and Perspectives………………………………………….……..164 
 
References…………………………………………………………………………...……..180 
 ix 
List of Tables 
 
 
Table 1: PDZ-binding motif of xYAP plays a role in epidermal and  
muscle differentiation……………………………………………………………………....101 
 
Table 2: Comparison of the sequence of wild-type to first mutated YAP  
(-141/+28) fragment……………………………………………………….………………..122 
 
Table 3: Comparison of the sequence of wild-type to second mutated YAP  
(-141/+28) fragment…………………………….…………………………………………..126 
 
 
 x 
List of Figures 
 
 
Figure 1: Protein-protein interaction domains of YAP……………………………………….4 
 
Figure 2: Validity of xYAP RT-PCR primer design………………………………………...38 
 
Figure 3: mRNA and protein expression of xYAP during Xenopus laevis development…...40 
 
Figure 4: Efficacy of xYAP-MOs in vitro…………………………………………………...42 
 
Figure 5: hYAP antibody recognized Xenopus laevis YAP…………………...…………….44 
 
Figure 6: Efficacy of xYAP-MOs in vivo……………………………………………………46 
 
Figure 7: Phenotype resulting from the individual xYAP-MOs…….……………………….48 
 
Figure 8: Phenotype resulting from a cocktail of the three xYAP-MOs…………………….51 
 
Figure 9: Phenotype resulting from injecting the xYAP MO cocktail into one cell  
of the 2-cell embryo………………………………………………………………………….53 
 
Figure 10: Efficacy of xYAP splice blocking MOs………………………………………….55 
 
Figure 11: Phenotype resulting from titration of xYAP-MO concentrations………………..57 
 
Figure 12: xYAP, mYAP, and hYAP gain-of-function in Xenopus laevis…………………..59 
 
Figure 13: Phenotype resulting from zYAP-MO…………………………………………….62 
 
Figure 14: Time-lapse video of 1-cell zYAP-MO injection…………………………………64 
 
Figure 15: qPCR analysis of the expression of genes required for germ layer formation  
in Xenopus laevis…………………..………………………………………………………...66 
 
Figure 16: In situ characterization of the xYAP morphants………………...……………….69 
 
Figure 17: Time-lapse video of epiboly progression in zYAP mRNA injected Danio  
rerio embryos…………………..…………………………………………………………….71 
 
Figure 18: Effects of zYAP gain-of-function in Danio rerio embryos……………………...73 
 
Figure 19: Altered Tropomyosin staining in xYAP gain-of-function  
Xenopus laevis embryos………………………………………………………………..…….76 
 
 
 xi 
Figure 20: TEM analysis of somitic muscle in xYAP gain-of-function  
Xenopus laevis embryos………………………..…………………………………………….78 
 
Figure 21: xYAP gain-of-function expands neural progenitor fields, while  
neural differentiation is inhibited…………………….....................…………………….…...80 
 
Figure 22: xYAP gain-of-function inhibits the expression of genes in the preplacodal 
ectoderm, epidermis, pre-migratory neural crest, and hatching gland…………………….....83 
 
Figure 23: xYAP expands pax3-expressing neural crest progenitors………..…..…………..86 
 
Figure 24: Endogenous xYAP resides at a novel 5’ regulatory region of pax3…………......89 
 
Figure 25: YAP does not co-immunoprecipitate with two other regions of Xenopus laevis 
genomic DNA…………………………………...…………………………………………...91 
 
Figure 26: Luciferase assay of the pax3 5’ regulatory region……………………………….94 
 
Figure 27: xYAP mutants used for experiments listed in Table 1…………………………...96 
 
Figure 28: Bar graphs for data listed in Table 1………………………………………....…..99 
 
Figure 29: Comparison between a TATA-containing and a TATA-less promoter…….…..109 
 
Figure 30: Alignment of myap proximal promoter region…………………….……………116 
 
Figure 31: Relative myap promoter activity in NIH3T3 fibroblasts……………………......118 
 
Figure 32: Relative myap promoter activity in M1 epithelial cells………………………...120 
 
Figure 33: Mutation of Sp1 site reduced myap promoter activity in fibroblasts…...………124 
 
Figure 34: Mutation of one putative Sp1 site reduced myap promoter activity in  
epithelial cells……………………………………………………………..…………….….127 
 
Figure 35: Annealing of myap promoter oligos for gel-shift analysis……………………...130 
 
Figure 36: Competitive gel-shift assay for Sp1 site in the myap promoter……………..….132 
 
Figure 37: Competitive gel-shift assay and supershift of Sp1……………………………...135 
 
Figure 38: PCR and western blot anlyses identify the genotypes of the  
MEF immortalized cell lines………………………………………..………………...…….149 
 
Figure 39: RT-PCR validation of microarray results……………………………………….154 
 
 xii 
Figure 40: Adding YAP back to YAP-/- MEFs and Jurkat cells increased  
adrenomedullin…………………………………..…………………………………………157 
 
Figure 41: Time course for mouse adrenomedullin promoter activity in MEF cell lines….159 
 
Figure 42: YAP is present on the mouse adrenomedullin promoter………...……………..161 
 
Figure 43: YAP binds to the C-terminus of hnRNP U……………………………………..168 
 
Figure 44: BAF155 and Brg1 can bind to the YAP WW1 domain……………………..….171 
 
Figure 45: Co-immunoprecipitation of YAP with Brg1……………………………………173 
 
Figure 46: Evolutionary conservation of YAP and TAZ…………………………………...176 
 
 
 
 xiii 
List of Abbreviations 
 
 
ADM  Adrenomedullin 
BAF155 Barrier-to-autoantigen factor 155 
BMP  Bone morphogenetic protein 
Brg1  Brahma related gene 1 
BSA  Bovine serum albumin 
Calcrl  Calcitonin receptor-like receptor 
Cbfa1  Core binding factor-1 
cDNA  Complementary deoxyribonucleic acid 
CFTR  Cystic fibrosis transmembrane conductance reglator 
ChIP  Chromatin immunoprecipitation 
CTD  Phosphorylated C-terminal domain of RNA polymerase II 
DMEM Dulbecco’s modified eagle medium 
DNA  Deoxyribonucleic acid 
EBP50  Ezrin/radixin/moesin (ERM)-binding phosphoprotein of 50kDa 
EGF  Epidermal growth factor 
EMSA  Electrophoretic mobility shift assay 
ERM  Ezin/radixin/moesin 
ESC  Embryonic stem cell 
FBS  Fetal bovine serum 
GST  Glutathione-S-transferase 
GFP  Green fluorescence protein 
HA  Hemagglutinin tag 
 xiv 
HATs  Histone acetyltransferases 
HG  Hatching gland 
hnRNP U Heterogeneous nuclear ribonuclear protein U 
hpf  Hours post-fertilization 
IgG  Immunoglobulin G 
IRdye  Infrared dye 
LATS  Large tumor suppressor 
LPA  Lysophosphatidic acid 
MITF  Microphthalmia-associated transcription factor 
MBS  Modified Barth’s Saline 
MEF  Mouse embryonic fibroblast 
MO  Morpholino 
NCP  Neural crest progenitors 
NHERF Na(+)/H(+) exchanger regulatory factor 
p53BP-2 p53-binding protein-2 
Pax3  Paired box 3 
PC  Polycystin 
PBS  Phosphate buffered saline 
PDZ  Postsynaptic density 95/Discs-large/Zonula occludens-1 
PECAM1 Platelet endothelial cell adhesion molecule 1 
PKD  Polycystic kidney disease 
PPARγ  Peroxisome proliferator-activated receptor-γ  
PVDF  Polyvinylidene fluoride 
 xv 
qPCR  Quantitative polymerase chain reaction 
RIPA  Radioimmunoprecipitation assay buffer 
RNA  Ribonucleic acid 
RT-PCR Reverse transcription-polymerase chain reaction 
SH3  Src homology domain 
Sp1  Specificity protein 1 
SV40  Simian virus 40 
TAZ  Transcriptional co-activator with a PDZ-binding motif 
TBS  TEAD binding site 
TBST  Tris-buffered saline with Tween 20 
Tbx-5  T-box transcription factor-5   
TEAD  Tea domain proteins 
TEF  Transcription enhancer factors 
TEM  Transmission electron microscopy 
TGF-β  Transforming growth factor-beta 
TTF-1  Thyroid transcription factor-1 
WISH  Whole mount in situ hybridization 
WWTR1 WW domain containing transcription regulator 1 
YAP  Yes-associated protein 65 
 
 xvi 
List of Symbols 
α Alpha 
β Beta 
γ Gamma 
Ψ Psi 
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The goal of my work is to better understand the role of YAP in vertebrate 
development. In this chapter, I provide background information regarding the initial 
identification of YAP, the in vitro identification of proteins shown to bind to the protein-
protein interaction domains present in YAP, and the consequences of deleting either YAP or 
its interacting proteins from the mouse. In addition, I provide background information 
regarding the YAP paralog, transcriptional co-activator with a PDZ-binding motif (TAZ), 
and briefly compare and contrast them. 
 
Yes-associated protein (YAP)  
c-Yes is a member of the Src family of tyrosine kinases. To investigate potential 
signaling targets and/or signaling regulators of c-Yes, Marius Sudol developed a polyclonal 
antibody to the Src homology domain (SH3) of c-Yes, which allowed for the generation of 
polyclonal anti-idiotypic antibodies, which were used for the isolation of proteins binding to 
the c-Yes SH3 domain (Sudol, 1994). A 65 kDa protein was precipitated from 
[35S]methionine labeled chicken embryo fibroblasts using these anti-idiotypic antibodies. 
Because high levels of c-Yes protein were present in the chick cerebellum and these anti-
idiotypic antibodies recognized the 65 kDa band, mRNA was isolated from the cerebella of 
2-week-old chicks and used for the creation of cDNA library in lambda gt11 phage. 
Screening this chick cerebellar cDNA library with the anti-idiotypic sera allowed for the 
identification of the first sequence data for Yes-associated protein 65 (YAP).  
Although YAP’s initial identification was based on its ability to bind to members of 
the Src tyrosine kinase family via its SH3 binding motif, it quickly became one of the 
founding members of a newly identified protein motif family, the WW domain containing 
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family. Upon database searches of a hinge region present between the spectrin repeats in 
Dystrophin, the product of the Duchenne muscular dystrophy locus, it was found that other 
genes such as Nedd-4, a ubiquitin ligase, Pin1, a proyl isomerase, Fe65, an adaptor protein 
with possible functions in regulating transcription, chromatin modification, cell growth, 
apoptosis, and axonogenesis, and YAP, an adaptor protein and transcriptional co-activator all 
contained a conserved stretch of amino acids that had two tryptophans spaced 20-22 amino 
acids apart. For this reason, this amino acid stretch was defined as the WW domain, which 
contains β-strands situated around four conserved aromatic amino acids and is 38 amino 
acids in length (Bork et al., 1994). The WW domain allows the binding of proteins 
containing a PPxY motif (Macias et al., 1996) and the known YAP interactors are 
summarized below (Figure 1). 
In one report, YAP was pulled out of a cDNA expression library using a fusion 
protein of Smad7, an established inhibitor of transforming growth factor-β (TGF-β) signaling 
(Ferrigno et al., 2002). To confirm binding, myc-Smad6 or myc-Smad7 were co-over-
expressed with a 6xHis-YAP in Cos cells, but pulldowns showed that only myc-Smad7 
interacted with YAP. However, deletion of the PPxY motif from Smad7 only reduced its 
binding capacity to YAP instead of eliminating its interaction entirely. To test the 
functionality of the interaction, a keratinocyte cell line was co-transfected with Smad7 and/or 
YAP and a Smad responsive luciferase vector, (CAGA)9-Lux, or its mutant form, in the 
presence or absence of TGF-β. While Smad7, expectantly, inhibited luciferase activity in the 
presence of TGF-β, the addition of YAP potentiated Smad7’s inhibition. The proposed 
mechanism of action for this inhibition was that YAP helps to inhibit TGF-β signaling by 
stabilizing the interaction of Smad7 with the activated receptor, TGF-β receptor I, and thus
 4 
Figure 1. Protein-protein interaction domains of YAP. Frog and zebrafish YAP possess 
the following functional and protein-protein interaction domains: a TEAD-binding site 
(purple), a LATS phosphorylation site (orange), two WW domains (red) that allow for PPxY 
binding, a Src Homology 3 (SH3)-binding domain (green), a coiled-coil region (blue), a 
transactivation domain (underline), and a PDZ-binding motif (pink).  hnRNP U (yellow) 
binding has only been experimentally tested with human YAP, but related sites are found in 
the fish and frog proteins. This diagram also illustrates the relative location of Xenopus laevis 
(x) and Danio rerio (z) morpholino (MO)-binding sites.  
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prevents receptor associated Smad (Smads1-3, and Smad5) phosphorylation. It should be 
noted that Smad7 is also capable of binding to the WW-domain containing ubiquitin ligases, 
Smurf1 and Smurf2, and recruiting them to activated TGF-β receptor I, which results in 
proteasomal degradation of the receptor (Chong et al., 2006, Kavsak et al., 2000). More 
recently, YAP and Smurf1 were shown to bind to Smad1/5 via their WW domains in the 
presence of bone morphogenetic protein (BMP) (Alarcon et al., 2009). Thus, YAP may play 
a role in modulating TGF-β and BMP signaling, both of which are involved in mesoderm 
induction and anterior-posterior (AP) axis formation. 
 ErbB-4, a receptor tyrosine kinase, is activated by members of the EGF (betacellulin, 
epiregulin, and HG-EGF) and the Neuregulin (neuregulin 1-4) families via homo- or hetero-
dimerization with ErbB-2. ErbB-4 binds YAP upon cleavage of its cytoplasmic tail and the 
two proteins translocate to the nucleus to activate ErbB-4 target genes. ErbB-4 knockout 
mice die by embryonic day 10.5 due to the lack of cardiac trabeculation, which is similar to 
mice lacking ErbB-2 and neuregulin-1 (Gassmann et al., 1995). In addition, mice lacking 
ErbB-4 exhibited a phenotype not seen in ErbB-2 and neuregulin-1 knockout mice, which 
was a defect in axon guidance in the central nervous system. Therefore, YAP could be 
involved in regulating cardiac muscle differentiation and axon guidance in the central 
nervous system. 
 p53-binding protein-2 (p53BP-2) was identified as binding to the first WW domain of 
YAP using a yeast two hybrid system. p53BP-2 contains a PPxY motif, four ankyrin repeats 
and one SH3 domain (Espanel et al., 2001). p53BP-2 binds to the DNA binding domain of 
p53 via its ankyrin repeats and SH3 domain, but not to common p53 mutants, which are 
associated with cancer (Gorina et al., 1996, Iwabuchi et al., 1994). Although the binding of 
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p53BP-2 and YAP could occur using GST-pulldowns as well as yeast and mammalian two-
hybrid assays, co-immunoprecipitations using antibodies to the proteins failed, despite 
immunoprecipitating their intended protein (Espanel et al., 2001). Further experiments 
showed that p53BP-2 could also interact with the SH3 domain of YAP in addition to its WW 
domain; however, a lack of co-IP of the two proteins makes the plausible interaction of the 
proteins transient at best.  
The WW domain of YAP was determined to bind to p73α via GST-pulldowns as well 
as co-immunoprecipitations from cells overexpressing tagged versions of each protein and 
endogenously (Strano et al., 2001). In addition, other p53 family members were found to 
bind to YAP, which included p73β, and p63α, whereas p73γ and p53 did not. Functionally, 
co-overexpression of YAP and p73α was capable of increasing the transcriptional activity of 
p73α, as evidenced by increased luciferase activity from Mdm2 and Bax reporter plasmids. 
In addition, an increase in the Bax protein was observed when YAP and p73α were co-
overexpressed. Point mutations in the p73α PPxY motif disrupted binding in GST-pulldowns 
and the activity of the Bax reporter plasmid confirmed the validity of the interaction.  
We found that endogenous YAP bound to the second PDZ domain of Na(+)/H(+) 
exchanger regulatory factor 1/ezrin/radixin/moesin (ERM)-binding phosphoprotein of 50 
kDa (NHERF1/EBP50) and localized to the apical membrane of polarized epithelial cells, 
thus linking apical membrane bound proteins to the actin cytoskeleton via the interaction 
between NHERF1 and ezrin (Mohler et al., 1999). 
YAP also contains a domain that interacts with the Tea domain (TEAD) proteins, also 
known as transcription enhancer factors (TEFs). TEADs are a family of transcription factors 
that contain the TEA domain DNA binding domain and are expressed ubiquitously. 
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However, some TEADs are expressed at higher levels at certain times during development, 
which suggests that each of them may possess unique functions under certain developmental 
contexts (Vassilev et al., 2001). From a variety of TEAD knockout mice, we now know that 
when some are absent, certain organs are more susceptible than others. Yet there is functional 
redundancy among the TEAD family members because when two TEADs are missing from 
the developing mouse, their developmental deficits are much more severe than their single 
knockout counterparts (Chen, Z. et al., 1994, Sawada et al., 2008).  
YAP’s interaction with TEAD-2 was identified using an unbiased approach to co-
purify TEAD-2 binding proteins with a tagged TEAD-2 protein using affinity 
chromatography and under otherwise naïve conditions.  While YAP was initially found to 
bind to TEAD-2, it was also capable of binding to all four mouse TEAD homologs. Using 
GST pulldowns, YAP was found to bind to the carboxy-terminus of mTEAD-2 (amino acids 
224-445), whereas TEAD-2 was found to bind to a defined amino terminus region of mYAP 
(amino acids 77-96). To test the functional ability of the TEAD-2/YAP interaction, a TEAD-
dependent promoter (pGT4Tluc) was used to co-transfect NIH-3T3 cells (endogenous YAP 
present) and EL4 cells (no endogenous YAP present) with increasing concentrations of 
TEAD-2 and with or without YAP. Results from these experiments showed that by 
increasing TEAD-2 concentrations, the measured TEAD-2 transcriptional activity decreased, 
which suggested that excess TEAD-2 competed with TEAD-2/YAP complexes for binding to 
the promoter. In the T-lymphocyte cell line, EL4, which was verified to not express TEAD or 
YAP, the addition of YAP alone was incapable of increasing TEAD-dependent promoter 
activity, yet when increasing amounts of TEAD-2 were added to this cell line the promoter 
activity steadily rose. However, when this same promoter activity was tested in NIH-3T3 
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mouse fibroblasts, which endogenously express TEAD-2 and YAP, increasing levels of YAP 
squelched this promoter activity. In agreement with YAP binding to all four mTEADs 
homologs, TEAD/YAP co-transfections with the TEAD responsive reporter confirmed that 
YAP can use any TEAD to activate the reporter plasmid, and when the TEAD binding site is 
deleted the promoter activity is lost.  
In an unbiased screen for binding partners to the proline rich amino terminus of 
hYAP (1-57), it was found that hnRNP U bound to this region of YAP (Howell et al., 2004). 
By radiolabeling cells with [32P]orthophosphate, performing hot and cold GST pulldowns 
with purified GST, GST-hYAP(1-57), GST-hYAP WW1 (162-217), and subsequent mass 
spectrometry analyses, hnRNP U was shown to bind to the proline rich amino terminus of 
hYAP. In addition, YAP and hnRNP U were capable of interacting only within the nuclear 
fraction even though both proteins can be found in the nuclear and cytoplasmic domains, 
suggesting that their association is regulated. The ascribed function of hnRNP U is varied 
and includes possibly regulating pre-RNA processing, mRNA transport, translation, and/or 
stability, transcriptional regulation via its interactions with RNP particles, whereby it can 
associate with histone acetylases (HATs), p300, and chromosomal attachment regions. The 
details however are still being worked out. What is known is that hnRNP U can be divided 
into three main interacting protein pieces. The amino terminus of hnRNP U interacts with 
DNA, the middle interacts with the phosphorylated C terminal domain (CTD) of RNA 
polymerase II, and the carboxy terminus interacts with nuclear actin and mRNA. 
Interestingly, hnRNP U can also associate with the E3 ubiquitin ligase, Skp1, Cul1, 
Roc1/Rbx/Hrt1 (SCFβ-TrCP) (Davis et al., 2002). Given that YAP can bind to so many 
different kinds of proteins, it is expected to be involved in a plethora of cell biological 
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processes; however, to best delineate YAP function in vivo, an understanding of the 
similarties and differences between its vertebrate paralog must be considered.  
 
Transcriptional co-activator with a PDZ-binding motif (TAZ)  
 Transcriptional co-activator with a PDZ-binding motif (TAZ), also known as WW 
domain containing transcription regulator 1 (WWTR1), is a YAP paralog that is only present 
in vertebrates. Comparing and contrasting the similarities and differences between these 
paralogs is important for delinating the functional significance of each in developmental 
contexts. TAZ was identified using radio-labeled translated cDNA pools to identify proteins 
that bound to 14-3-3 (Kanai et al., 2000). The mouse form of TAZ is forty-five percent 
identical at the amino acid level to mouse YAP. 
YAP and TAZ are similarly expressed in the heart, lung, liver, and kidney of mice by 
Northern blot analysis; however, analyses using RT-PCR suggest that YAP and TAZ are 
more broadly expressed (Kanai et al., 2000). TAZ is similar to YAP in that it contains a 
phosphorylation site that permits the binding of 14-3-3 in the N-terminal region of the 
protein, a TEAD binding region, a single WW domain in the middle, and a PDZ interaction 
motif at the C-terminus. However, YAP differs from TAZ in that it contains a second WW 
domain, an SH3 binding motif as well as a proline-rich N-terminus. The binding of 14-3-3 to 
mTAZ requires the phosphorylation of serine eighty-nine; however, that binding reduces its 
transcriptional activity by sequestering it away from the nucleus and holding it in the 
cytoplasm. Surprisingly, it was found that deletion of the PDZ-binding motif at the extreme 
C-terminal region of TAZ eliminated TAZ-mediated transcriptional co-activation. Because 
we previously showed that YAP bound to NHERF1, Kanai et al. used direct binding assays 
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to test the binding of YAP and TAZ to NHERF1 and NHERF2 (Kanai et al., 2000, Mohler et 
al., 1999). YAP was capable of binding to both, but TAZ seemed to selectively bind to 
NHERF2. TAZ and NHERF2 did not, however, co-localize within the cell’s punctate nuclear 
bodies, suggesting there must be other nuclear PDZ containing proteins responsible for 
regulating its transcriptional co-activation.  
Similarly to YAP, TAZ is often shown to associate with other proteins through one of 
its protein-protein interaction domains. In contrast, the two paralogs are sometimes unable to 
bind to the same proteins, suggesting functional specificity of the paralogs whereby one is 
unable to compensant for the function of the other. One study illustrated an interaction with 
the N-terminus of thyroid transcription factor-1 (TTF-1), also known as Nkx2.1, via its WW 
domain (Park, K. S. et al., 2004). TTF-1 is important for regulating and activating genes, 
such as surfactant proteins A, B, and C in the lung and thyroglobulin, thyroperoxidase and 
sodium-iodide symporter in the thyroid. TTF-1 null mice lacked thyroid and pituitary glands, 
while also exhibiting defects in the lung and ventral forebrain. Overexpression of TTF-1 in 
alveolar type II cells in the lungs of transgenic mice resulted in emphysema, epithelial cell 
hyperplasia, and inflammation. In the presence of TAZ, the efficacy of TTF-1’s 
transcriptional activity on the SP-C promoter was increased when co-transfected into both 
MLE-15, a large T antigen immortalized mouse lung epithelial cell line, and HeLa cells 
(Park, K. S. et al., 2004). 
TAZ may bind Runx2, also known as core binding factor 1 (Cbfa1), via its WW 
domain and the PY motif of Runx2 (Cui et al., 2003, Zaidi et al., 2004). Runx2 belongs to 
the Runt family of transcription factors and controls the expression of osteoblast specific 
genes, such as osteocalcin. Runx2 is critical for proper bone development. Runx2 null mice 
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lack differentiated osteoblasts and their progenitors (Komori et al., 1997, Otto et al., 1997) 
and this can be partially rescued by transgenic overexpression (Takeda et al., 2001). Cui et 
al. presented evidence for a functional interaction between TAZ and Runx2, which resulted 
in the upregulation of osteocalcin promoter activity (Cui et al., 2003). Although Zaidi et al. 
also showed the TAZ/Runx2 interaction, the interaction repressed osteocalcin promoter 
activity in their studies (Zaidi et al., 2004). Further support for the TAZ/Runx2 interaction 
regulating bone development was shown in TAZ morphant zebrafish, whereby bone 
development was reduced as evidenced by the lack of skeletal ossification (Hong et al., 
2005). More importantly in this report, TAZ was demonstrated to be at the crossroads of 
mesenchymal stem cell differentiation into either osteoblasts (bone) or adipocytes (fat). 
BMP-2 is a known inducer of osteoblast differentiation and was shown to induce TAZ 
mRNA and protein. The interaction of Runx2 with TAZ promoted bone formation via 
upregulation of the osteocalcin promoter, while inhibiting the transcriptional activity of the 
peroxisome proliferator-activated receptor γ (PPARγ), a ligand-activated transcription factor 
involved in adipocyte differentiation.  
The proposal that TAZ is involved in cardiac and limb development came form the 
observation that it could directly bind to the T-box transcription factor, Tbx5, and activate 
Tbx5-dependent transcription (Murakami et al., 2005). In addition, TAZ was shown to 
physically associate with the histone acetyltransferases (HATs), p300 and PCAF, and thus 
may activate Tbx5-dependent transcription by some unknown mechanism via binding to 
these HATs.  Interestingly, YAP could also stimulate Tbx5-dependent transcription, but 
could not directly associate with Tbx5. However, TAZ and YAP can form heterodimers with 
one another via their coiled-coil domains. TAZ was capable of forming a homodimer with 
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itself, while YAP was not. Mutational analysis indicated that TAZ could interact with Tbx5 
via multiple domains, including the C-terminus of TAZ. Finally, TAZ was incapable of 
binding to Tbx5 truncations that are associated with Holt-Oram syndrome, which is a disease 
associated with cardiac and upper limb abnormalities.  
Using a yeast two-hybrid screen with full-length Pax3 as bait, it was found that TAZ 
could bind to Pax3 via the WW domain of TAZ and a C-terminal PY motif in Pax3 
(Murakami et al., 2006). However, the PY motif was non-essential for the coactivation of a 
Pax3 target gene, microphthalmia-associated transcription factor (MITF), but the C-terminal 
region of Pax3 was essential, suggesting other protein interactions may be involved in 
Pax3/TAZ-mediated transcriptional activation. In Chapter II, I will demonstrate that YAP is a 
regulator of Pax3 transcription. 
Like YAP, TAZ interacts with intracellular effectors of TGF-β signaling. TAZ can 
bind to the Smad2/3 complex (Varelas et al., 2008), which can mediate activation of the 
TGF-β/Activin/Nodal receptors (Moustakas et al., 2009). TAZ interacted more strongly with 
the receptor activated Smad2/3/4 complex than with activated Smad1 (Varelas et al., 2008), 
which resulted in the recruitment of the TAZ/Smad2/3/4 complex to the TGF-β response 
elements in the promoter of Smad7.  
Loss of TAZ in human embryonic stem cells (hESCs) resulted in the loss of Oct4 and 
Nanog, both pluripotency markers, and pluripotency is controlled via Smad2/3 signaling in 
hESCs. Interestingly, knockdown of TAZ in mouse embryonic stem cells (mESC) did not 
affect Oct or Nanog levels or their pluriopotent state, which correlates with the fact that 
pluripotenty in mESCs is controlled by Smad1/5/8. Finally, in the absence of TAZ, activated 
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Smad2/3/4 complexes do not accumulate in the nucleus and thus do not activate target genes 
(Hong et al., 2005, Varelas et al., 2008). 
 
Do YAP and TAZ share developmental functions?  
The YAP paralog, TAZ (WWTR1), is expressed throughout development. Mice null 
for TAZ survived until birth, although 35-50% did not survive past the age of weaning 
(Hossain et al., 2007). TAZ null mice were smaller in stature, exhibited lower body weights, 
and died earlier (10-12 months) than wild type or heterozygous animals. Although severe 
defects in bone development were reported in TAZ-morphant zebrafish, only minor skeletal 
defects were observed in TAZ null mice. More persistent were the presence of enlarged, 
anemic kidneys, which were filled with cysts, primarily of glomerular origin. The formation 
of these cysts began as early at E15.5, while cyst number and size increased with age.  
In a report by a separate group, half of the expected number of TAZ null mice was 
recovered at birth, indicating partial embryonic lethality (Tian et al., 2007). Surviving TAZ 
null mice were smaller and inactive compared to wild type and heterozygous littermates, yet 
production of bone and fat was relatively normal. Similar to the previous report, the 
surviving TAZ null mice developed severe polycystic kidney disease (PKD), also of cortical 
origin, but with the additional phenotype of severe pulmonary disease. Since 85% and 15% 
of human autosomal dominant polycystic kidney disease are due to mutations in PKD1 (PC1) 
and PKD2 (PC2), respectively, the levels of the associated mouse genes, pc1 and pc2, 
respectively, were examined. Although similar protein levels of PC1 were observed in wild 
type and TAZ null animals, approximately two fold increased levels of PC2 were found in 
the kidneys of TAZ null mice. Interestingly, the levels of pc2 transcripts were actually 
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reduced, suggesting that TAZ did not directly regulate the transcription of pc2, but instead 
controlled a poststranscriptional mechanism for regulating the levels of PC2 protein. 
Similarly, PC2 protein levels were increased in TAZ morphant zebrafish, which also 
developed “large bilateral cystic dilations in the pronephric tubules.”  Further investigation 
into TAZ’s role in regulating PC2 protein levels revealed that TAZ interacts with PC2 via its 
coiled-coil domain and possesses a phosphodegron motif, which is phosphorylated by an 
unknown kinase, recognized by β-Trcp, and allows for TAZ’s incorporation into the SCFβ-
TrCP ubiquitin ligase complex whereby PC2 is targeted for degradation. Thus, without TAZ, 
PC2 is not brought into the ubiquitin ligase complex and not targeted for degradation. 
Another interesting observation from this study was that mutation of TAZ’s phosphodegron 
motif or siRNA mediated reduction of β-Trcp resulted in augmented TAZ protein levels, 
suggesting that TAZ may also be directly targeted for ubiquitin-mediated degradation. It is 
interesting to note here that hnRNP U, which binds to YAP and not TAZ, can bind to SCFβ-
TrCP ubiquitin ligase, suggesting an even more complex role for YAP’s regulation of cellular 
components (Davis et al., 2002, Howell et al., 2004). 
 Much less is known about the role of YAP in developmental processes. By RT-PCR 
analysis, myap mRNA was detected as early as embryonic day 3.5 and was maintained 
throughout embryonic development (Morin-Kensicki et al., 2006). In situ hybridization 
analyses revealed that yap mRNA expression was ubiquitous, but dynamic throughout 
development. yap mRNA was present in the extraembryonic ectoderm, epiblast, and nascent 
mesoderm at E6.5 (the beginning of mouse gastrulation), abundant in the extraembryonic 
mesoderm and ectoderm and lower in visceral and definitive ectoderm at E7.5. By E8.5, 
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when the chorion and allantois fuse, yap remained ubiquitous, but was more strongly 
expressed at the distal tip of the allantois.  
 Using homologous recombination, we targeted the yap allele with a targeting 
construct intended to disrupt transcription at the yap locus. Once embryonic stem cells were 
electroporated, selected, and screened for the integration event, mice carrying the allele were 
established via blastocyst embryonic stem (ES) cell injection. Germ line transmission from 
chimeric mice was confirmed by the heterozygosity of the targeted allele. These 
heterozygotes showed no obvious malformations and were then crossed to one another to 
produce genetically altered offspring at the expected Mendelian ratios for the targeted YAP 
allele. No YAP-null offspring were recovered postnatally, while less than 1% were recovered 
after E10.5; however, the nearly expected 23% of YAP-null embryos were recovered 
between E6.5-9.5. Therefore, we concluded that mice lacking YAP rarely survived past E9.5. 
This is in stark contrast to TAZ-null mice, indicating that these two closely related proteins 
have different developmental roles. 
YAP-null embryos demonstrated developmental malformations beginning at E7.5.  
YAP-null mice appeared smaller in stature compared to wild type E7.5 mice and exhibited 
constriction at the embryonic-extraembryonic boundary or a profound separation between the 
hypoblast and the epiblast; however, most of the embryos at this stage did possess a properly 
formed amnion and chorion. By E8.5, the YAP-null embryos’ body axes were shorter and 
wider, the anterior epithelium was improperly folded, the allantois failed to fuse with the 
chorion, and there was evidence of caudal dysgenesis. E9.5 embryos showed defective 
ventral closure, a failure to make its emblematic turn, a disorganized anterior neurepithelium, 
a swollen allantois, and a ruffled yolk sac. Detailed analyses of hematoxylin and eosin 
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stained sections showed a disorganized embryonic mesoderm and confirmed separation of 
the embryonic-extraembryonic border in E7.5 embryos, while E8.5 embryos showed 
excessive folding of the anterior neurectoderm and a thinner epiblast-like epithelium 
overlying the mesoderm along the streak region, compared to wild type embryos. Although 
E8.5 embryos showed the presence of a node, anterior somites, primitive heart tissue, 
allantois, and yolk sac mesodermal cells, the blood islands within the yolk sac were atypical, 
suggesting potential defects in the yolk sac vascular system. Using immunostaining for 
Platelet endothelial cell adhesion molecule-1 (PECAM1), which is a marker for endothelial 
cells, and whole mount in situ hybridization (WISH) for alpha globin, a marker for 
erythrocyte precursors (erythroblasts), we showed that although both endothelial cells and 
erythroblasts were specified in the yolk sac, the primitive vascular plexus was disorganized. 
To determine whether anterioposterior patterning was disrupted in the YAP-null mice, two 
markers, fgf8 and hesx1, were used for WISH. Normally, fibroblast growth factor-8 (fgf8) is 
expressed at the anterior neurectoderm, midbrain-hindbrain boundary, branchial arches, and 
tail bud, whereas hesx1 marks the most anterior portion of the neurepithelium. Several 
restricted bands of fgf8 staining and anterior staining for hesx1 was observed in YAP-null 
mice. These results indicate that although the embryos are morphologically atypical, anterior 
and posterior patterning was maintained. Because the body axis of YAP-null embryos were 
shorter, yet broader than wild type embryos, WISH staining for brachyury was performed. 
Although brachyury expression was present in the streak, tailbud, and midline, it was 
unusually wide and discontinuous. 
Given these findings, we postulated that YAP could affect axis elongation through 
alterations in the following: proliferation, apoptosis, morphogenetic movements during 
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gastrulation, or gene expression changes. Results from proliferation and apoptotic assays did 
not discern appreciative differences between null and wild type embryos. The last two 
possible mechanisms are addressed in Chapter II.  
YAP-null mice are more severely affected during early development than are TAZ- 
null mice. In fact, taz mRNA levels are normal in YAP-null embryos, indicating that it can 
not fully compensate for loss of YAP. However, since YAP-/- and TAZ-/- double mutant mice 
die before the morula stage (16-32 cell stage), the presence of TAZ in YAP-null mice does 
partially compensate for the early function of YAP (Nishioka et al., 2009). Thus, although 
YAP and TAZ share many structural features they are likely to have different developmental 
roles. In hindsight, this may not be so surprising given that the vertebrate YAP homolog is 
more closely related to that of the invertebrate homolog than is TAZ and thus may have 
retained the necessary functions established in earlier evolution before the duplication event 
that resulted in the presence of YAP and TAZ within vertebrates. Thus, we began a series of 
studies to elucidate the developmental function of YAP. 
 
Comparison of YAP-null mice to protein interacting-null mice 
To begin to uncover the developmental function of YAP, we asked whether mouse 
lines that were null for proteins known to interact with YAP shared any developmental 
phenotypes with YAP-/- mice. In this section, I briefly describe some of the phenotypes 
associated with the knockout mice of YAP’s interacting partners.  
While deletion of the Src family tyrosine kinase, Yes, resulted in mice that appeared 
viable and fertile with no apparent adverse phenotype (Stein et al., 1994), Src-null mice die 
within weeks of birth (Soriano et al., 1991). They also develop osteopetrosis and fail to 
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properly remodel bone due to defects in osteoclast function (Lowe et al., 1993, Soriano et al., 
1991). Mice lacking Fyn die around birth and exhibited postnatal defects, such as defective 
T-cell activation (Stein et al., 1992). Interestingly, the number of perinatal deaths increases in 
mice with compound mutations, illustrating the functional redundancy of the Src family 
tyrosine kinase (SFK) family members (Stein et al., 1994). Triple (Src, Fyn, and Yes) mutant 
mice were recovered at the expected frequency of one in sixteen at E9.5, but these embryos 
were one-half the size of wild type embryos, had not undergone turning, and were beginning 
to be resorbed (Klinghoffer et al., 1999). They also exhibited a wavy neural tube, defective 
chorioallantoic fusion, and yolk sacs that were properly vascularized, illustrating that mice 
lacking Src/Fyn/Yes had phenotypes similar to those seen in YAP-null mice. 
Deletion of the MH2 domain within Smad7 caused the majority of the homozygous 
mutant mice to die in utero due to multiple defects in cardiovascular development, while any 
surviving mutant mice exhibited impaired cardiac functions and severe arrhythmia (Chen, Q. 
et al., 2009). Deletion of exon 1 of Smad7 resulted in mice that were viable, yet smaller on 
an outbred mouse CD-1 strain (Li, R. et al., 2006). Furthermore, B cells from these Smad7 
mutant mice showed increased TGF-β signaling as evidenced by increased phosphorylated 
Smad2. None of these defects are similar to YAP-null embryos. 
ErbB-4-null mice fail to differentiate the heart into trabeculae, which leads to reduced 
blood flow and death at E10.5 (Gassmann et al., 1995). This phenotype is shared by embryos 
lacking ErbB-2 and neuregulin-1 (Lee, K. F. et al., 1995, Meyer et al., 1995).  ErbB-4-null 
mice also exhibit failures in innervation of the hindbrain, while ErbB-2-null mice exhibited 
defects in the development of cranial neural-crest-derived sensory ganglia and motor nerves 
resulting from a failure to produce and ensheath the nerves with myelin (Gassmann et al., 
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1995, Lee, K. F. et al., 1995, Park, S. K. et al., 2001). YAP-null mice are lethal prior to these 
developmental events. 
No p53-binding protein-2 (p53BP-2) homozygous mutant mice were recovered as 
early as E6.5, illustrating that p53BP-2 is essential for early mouse development (Kampa et 
al., 2009). Heterozygous p53BP-2 mice appeared to develop normally; however, they were 
more susceptible to the development of spontaneous tumors as they aged. The creation of a 
different p53BP-2 mutant mouse revealed that fewer (6.4%) than the expected 25% 
homozygous mutant mice were recovered at birth and that the ones that were not recovered 
survived until E18.5 with defects in the heart and central nervous system (Vives et al., 2006). 
These heterozygous p53BP-2 mutant mice also developed normally and exhibited a higher 
frequency in the formation of spontaneous tumors. YAP-null mice share a similar early 
lethality. 
Mice lacking all isoforms of p73 exhibit hippocampal dysgenesis, hydrocephalus, 
chronic infections and inflammation, as well as abnormalities in pheromone sensory 
pathways (Yang et al., 2000). Mice lacking p63 are born alive but exhibit complete loss of or 
truncation of their limbs, defective differentiation of the apical ectodermal ridge, and 
defective stratification and differentiation of the skin (Mills et al., 1999, Yang et al., 1999). 
In addition, hair follicles, teeth, and mammary glands are absent in p63 homozygous mutant 
mice due to defective epidermal-mesenchymal interactions. Based on the phenotypes of these 
p63 homozygous mutant mice, it was concluded that p63 is essential for the proper 
maintenance of epidermal progenitors. These phenotypes all occur later than the YAP-null 
phenotypes, but as I will demonstrate in Chapter II, we also have evidence that YAP 
maintains certain ectodermal progenitors. 
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NHERF1/EBP50 mutant male mice developed normally except for exhibiting 
increased urinary excretion of phosphate due to the mislocalization of the sodium-phosphate 
co-transporter type IIa to internal sites within the renal proximal tubule cells compared with 
its normal apical localization (Shenolikar et al., 2002). NHERF1 mutant female mice 
weighed 30-50% less than their wild type littermates, died 30-35 days after birth, and 
exhibited reduced bone density, muscle weakness and in some cases hydrocephaly. It should 
also be noted that “attempts to generate an isogenic strain of NHERF1-/- mutant mice in the 
F129/Svj strain yielded few, small litters (two to three animals)” (Shenolikar et al., 2002). In 
contrast, another NHERF1-/- mutant mouse generated by a different group did not see the 
dramatic phenotypes seen in their females, yet they did admit that some females were weaker 
and eventually died earlier (Morales et al., 2004). However, this group did confirm the 
phosphate wasting phenotype and expanded the phenotype to include a reduction of ezrin–
radixin–moesin (ERM) proteins in the epithelial cells of the small intestines and the cortical 
brush border membranes of the kidney. Again, the phenotypes associated with these null-
mice all occur later than the primary defects seen in YAP-null embryos. 
YAP is capable of binding to all four mammalian TEAD transcription factors. Both 
YAP and the TEADs are broadly expressed during development, while their expression 
levels are dynamic throughout development. Homozygous TEAD1 mutant mice die by E11.5 
with heart defects due to improper cardiac muscle growth, not its differentiation (Chen, Z. et 
al., 1994). Homozygous TEAD2 mutant mice exhibited no discernable phenotype from wild 
type littermates (Sawada et al., 2008). However, TEAD1 and TEAD2 double mutant mice 
exhibited general growth retardation, displacement of the paraxial and lateral plate 
mesoderm, defective notochord development, and defective yolk sac vasculogenesis. The 
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defective notochord development in TEAD1 and TEAD2 double mutant mice is likely due to 
their regulation of a FoxA2 enhancer in the notochord (Sawada et al., 2005). TEAD4 mutant 
mice died during the stages of pre-implantation without forming a blastocoele, failed to 
differentiate trophoblast giant cells, and ICM specific genes were expressed in all 
blastomeres, indicating that TEAD4 is essential for trophectoderm specification (Nishioka et 
al., 2008, Yagi et al., 2007). Although no data on TEAD3 mutant mice yet exists in the 
literature, personal communication with H. Sasaki suggests that TEAD3-/- mice appear 
normal and fertile (Sawada et al., 2008). Alternatively, published data suggests that TEAD3 
could be essential for the formation of the placenta and differentiation of cardiomyocytes 
(Brunskill et al., 2001, Jiang, S. W. et al., 1999, Maeda et al., 2002, Peng et al., 2004).  
Mice carrying a hypomorphic mutation in hnRNP U resulted in postimplantation 
lethality (Roshon et al., 2005). While E3.5-E6.5 homozygous mutant mice appeared no 
different from their wild type and heterozygous littermates, by E7.5 hnRNP U homozygous 
mutant mice appeared similar to those of wild type E6.5 mice. By E8.5, wild type mice had 
begun to undergo organogenesis and the neural folds, primitive heart, and somities were 
present, while homozygous hnRNP U mutant mice appeared not to have progressed further in 
development, but exhibited an expansion of the extraembryonic tissue. In fact, homozygous 
hnRNP U mutant mice possessed an enlarged allantois, which was likely due to the failure of 
the chorion to fuse with the allantois.  
In this section, I briefly described some of the phenotypes associated with the 
knockout mice of YAP’s interacting partners; however, only Src/Fyn/Yes, p53SP-2, p73, 
TEAD, and hnRNP U mutant mice exhibited phenotypes even closely resembling those of 
YAP-null embryos. Therefore, in order to best understand YAP’s role in early vertebrate 
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development, it was imperative that I perform a series of knockdown and gain-of-function 
experiments in animal models more amenable to early developmental invesitgations. 
Chapter II – YAP expands neural progenitors and regulates pax3 
expression in the neural plate border zone 
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Introduction 
Yes-associated protein 65 (YAP) contains multiple protein-protein interaction 
domains and functions as both a transcriptional co-activator and as a scaffolding protein. 
YAP was first identified and named based on its association with the Src-family tyrosine 
kinase and proto-oncogene, c-Yes (Sudol, 1994). YAP is a founding member of the WW 
domain-containing protein family (Bork et al., 1994, Sudol et al., 1995). The WW domain 
allows the binding of proteins containing a PPxY motif (Macias et al., 1996). Proteins shown 
to bind to YAP via its two WW domains include: p53 family members (p73α, p73β, p63 
(Strano et al., 2001); Smad7 (Ferrigno et al., 2002); Runx2 (Yagi et al., 1999); and ErbB-4 
(Komuro et al., 2003, Omerovic et al., 2004).  
In addition to the two WW domains, YAP also contains other protein-protein 
interaction domains (Figure 1). Proteins that interact at the N-terminus of YAP include 
hnRNP U, a nuclear ribonucleoprotein shown to be important for RNA polymerase II 
transcription (Howell et al., 2004, Kukalev et al., 2005), the TEA domain-containing 
transcription factor (TEAD/TEF) family (Vassilev et al., 2001), and the Large tumor 
suppressor (LATS). The phosphorylation event involving LATS allows for the binding of 14-
3-3, which leads to the subsequent sequestration of YAP to the cytoplasm (Zhao et al., 2007). 
At its C-terminus, YAP contains a postsynaptic density 95, discs large, and zonula 
occludens-1 (PDZ)-binding motif that allows for binding to PDZ domain-containing proteins.  
 Our initial interest in YAP came from the finding that YAP bound to the second PDZ 
domain of Na(+)/H(+) exchanger regulator factor 1/ezrin/radixin/moesin (ERM)-binding 
phosphoprotein of 50 kDa (NHERF1/EBP50) and co-localized to the apical membrane of 
polarized airway epithelia along with Cystic fibrosis ransmembrane conductance regulator 
 26 
(CFTR) and c-Yes (Mohler et al., 1999). To determine the in vivo importance of this 
scaffolding complex, we used homologous recombination to remove YAP from the mouse 
and found that few embryos survived past embryonic day 8.5 (E8.5), a much earlier time 
point than would be expected for an associated lung development phenotype (Morin-
Kensicki et al., 2006). Detailed analyses of these mice illustrated that they suffered from 
defects in yolk sac vasculogenesis, chorioallantoic fusion, and anterior-posterior (A-P) axis 
elongation. 
Given that YAP knockout mice struggled to progress normally through early 
development, in part because of nutritional deficiencies, we sought to better characterize a 
role for YAP during this time period by using embryos that develop externally: Xenopus 
laevis and Danio rerio. YAP morpholino (MO)-mediated loss-of-function resulted in a delay 
of mesoderm induction and severely impaired A-P axis elongation, phenotypes that were 
similar to YAP-/- mice. YAP gain-of-function experiments in Xenopus laevis expanded the 
progenitors of the neural plate and neural plate border zone, while concomitantly inhibiting 
expression of later markers of tissues derived from the neural plate border zone (neural crest, 
preplacodal ectoderm (PPE), hatching gland), as well as epidermis, and somitic muscle. 
Through loss- and gain-of-function experiments and endogenous chromatin 
immunoprecipitations (ChIP) for YAP, we show that YAP directly regulates pax3 expression 
via association with TEAD1 (N-TEF) and ultimately localizes to a highly conserved, 
previously undescribed, TEAD-binding site within the 5’ regulatory region of pax3. Finally, 
structure/function analyses revealed that the PDZ-binding motif of YAP contributes to the 
inhibition of epidermal and somitic muscle differentiation, but a complete, intact YAP 
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protein is required for expansion of the neural plate and neural plate border zone progenitor 
pools. 
 
Materials and Methods 
Animal use and ethics statement 
All experimental procedures described in this study followed the U.S. Public Health 
Service Policy of Humane Care and Use of Laboratory Animals and were approved by the 
Institutional Animal Care and Use Committee at the National Institutes of Health (NHLBI 
Animal Study Protocol: #H-0063), University of North Carolina at Chapel Hill (IACUC ID: 
10-277.0), and the George Washington University (GWU Animal Study Protocol: #A-3205). 
 
xYAP and morpholinos 
A Xenopus laevis full-length cDNA clone (XL211h05) of yes-associated protein 65 
(xyap) was obtained from the National Institute for Basic Biology (Japan) and sequenced in 
both directions (GenBank Accession #FJ979828). Three morpholinos, MO1 (GGA GGT 
GGG AGC TAG GAC AGC GG), MO2 (GGA GAG GAC GCG GTA GGA GAC TGT G), 
and MO3 (GGG CTC CAT GGC TGC GGG GAG GTG G), were designed to the 5’UTR of 
xyap for translational blocking (Figure 1; GeneTools). Two splice blocking and putative 
early translational truncation MOs, exon 1 (GTA GAG GAG CAT ATA CCT GCC GTG A) 
and exon 2 (CCT GCA AAG AAC AAG TGG GAC AAT A) (GeneTools) were designed 
across exon/intron boundaries. In vitro translation reactions were performed using the TnT 
Quick Coupled Transcription/Translation System (Promega), according to the manufacturer’s 
protocol. Each MO (80 ng) was injected into in vitro fertilized one-cell Xenopus laevis 
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embryos according to established methods (Sive et al., 2000). To observe phenotypes 
associated with lower MO concentrations (0, 1.25, 2.5, 5, 10, 20, and 40 ng total), a cocktail 
of all three (MO1, MO2, and MO3) translational blocking MOs was injected into in vitro-
fertilized one-cell sibling embryos.  
 
xYAP RT-PCR 
Using Xenopus tropicalis genomic scaffolds containing xyap, exon-intron boundaries 
were determined with Spidey (http://www.ncbi.nlm.nih.gov/spidey/) by aligning the 
scaffolds with the xyap mRNA. The Primer3 program was used to generate a pair of primers 
(Forward: GAG CCC TCA GAC TGG AGT GTT G, Reverse: TCA TGC TCA ATC CGC 
TTT CAG T) between exon 6 and exon 8 for use in reverse transcriptase-polymerase chain 
(RT-PCR) reactions. Twenty Xenopus laevis embryos were collected for each of the 
following developmental stages (Nieuwkoop et al., 1994): unfertilized egg, 2, 3, 6, 7, 9, 10, 
11, 12, 16-17, 19-21, 21-23, 23-25, 26-28, 29-30, 36-38, 40 and stored in RNAlater 
(Ambion) at -20°C. Embryos were removed from the RNAlater (Ambion) and homogenized 
in 1 mL of Trizol reagent (Invitrogen) and RNA was isolated according to the manufacturer’s 
specifications. Prior to precipitation, glycogen was added to the aqueous phase as a co-
precipitant. After drying, the RNA pellet was resuspended in 50 µl of nuclease-free water 
and quantified by its absorbance at 260 nm, while its purity was based on the ratio of 
A260/A280.  
3 µg of RNA from each Xenopus laevis stage was treated with DNase I (Promega) 
according to the manufacturer’s specifications and heat inactivated at 65°C for 10 minutes. 
These samples were split in half with half being used to synthesize cDNA and the other half 
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used for a no reverse transcriptase control.  Reverse transcription was performed using 
random hexamer priming and Superscript II reverse transcriptase (Invitrogen) according to 
the manufacturer’s specifications. 1 µl of each reverse transcribed cDNA template, no-
reverse transcriptase control, and no template control was added to a 50 µl PCR reaction 
cocktail, denatured at 94°C for 2 minutes, and cycled 32 times as follows: 94°C for 30 sec, 
55°C for 30 sec, and 72°C for 1 min. 15 µl of each PCR reaction was electrophoresed on a 
2% agarose gel and the resulting 305 base pair products were visualized using ethidium 
bromide and ultraviolet light. As a loading control, a primer set (Forward: GGG ATA ACA 
TTC AGG GTA TC, Reverse: CAT GGC GGT AAC TGT CCT) for Xenopus laevis histone 
H4 was used for PCR amplification from the reverse transcribed cDNA template and 100 ng 
of xyap plasmid DNA was used as a positive control.   
Genomic DNA was isolated from thirty stage 29 Xenopus laevis embryos stored in 
RNAlater at -20°C using the protocol for isolating genomic DNA from Ambion. The 
resulting pellet was resuspended in 200 ul of nuclease free water, quantified by measuring 
A260, and treated with RNase-T1 (Sigma). Amplification of the Xenopus laevis genomic 
product was performed using the Expand Long Template PCR System (Roche) according to 
the manufacturer’s protocol. 
 
Cloning methods and constructs 
For use in all of our gain-of-function analyses, we initially cloned an HA tag (ATG 
TAC CCA TAC GAT GTT CCA GAT TAC GCT) into the XhoI and EcoRV sites of the 
pSP64TXB vector so that proper expression could be detected by western blot analysis. xyap 
and xtead1 were subcloned in frame with the HA tag into the EcoRV and NotI sites of the 
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pSP64TXB-HA vector. A set of xYAP mutant constructs, which included a constitutively 
active form of xYAP (cActive xYAP) with a mutated LATS phosphorylation site (S98A), a 
deletion (aa 61-81) of the TEAD-binding site (xYAPΔTBS), a deletion (aa 78-161, aa 199-
236) of the WW domains (xYAPΔWW), a deletion (aa 1-90) of the entire N-terminus 
(xYAPΔN), and a deletion (aa 455-459) of the PDZ-binding motif at the C-terminus 
(xYAPΔC), were also subcloned into the pSP64TXB-HA vector at the EcoRV and NotI sites. 
 
Gain-of-function analyses 
  For initial gain-of-function analyses, the animal poles of one-cell Xenopus laevis 
embryos were injected with 2 ng of in vitro-transcribed ha-xyap mRNA (mMessage 
Machine, Ambion). For additional gain-of-function analyses, two-cell Xenopus laevis 
embryos were co-injected with 1 ng of in vitro-transcribed ha-xyap or ha-xyap mutant 
mRNAs and 100 pg of in vitro-transcribed nls-β-galactosidase mRNA into the lateral, 
animal pole of one of the two blastomeres. Similarly, 100 pg of the in vitro-transcribed ha-
xtead1 (xn-tef1) (Naye et al., 2007) or 100 pg of ha-xyap mRNAs, were injected alone or in 
combination.  
 
Western blots 
Embryos were injected at the 1-cell stage with a cocktail of the three (MO1, MO2, 
and MO3) translational blocking xYAP MOs (40 ng or 80 ng total) or the standard control 
MO (40 ng or 80 ng). These sibling embryos were allowed to develop until control embryos 
reached stage 15. Whole embryo lysates were snap frozen in a dry ice/ethanol bath and lysed 
in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium 
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0.1% SDS) containing a protease inhibitor cocktail (Roche). Subsequently, Freon (1,1,2-
trichlorotrifluoroethane, Sigma-Aldrich) was used to remove the yolk from the samples, 
which were then boiled for 5 min and stored at -80°C. Total protein concentrations were 
quantified using the BCA Protein Assay Kit (Pierce), according to the manufacturer’s 
protocol. Equal amounts of protein were loaded onto a 10% SDS-PAGE gel, separated by 
electrophoresis, transferred to a PVDF membrane, and probed for xYAP using an affinity 
purified rabbit anti-YAP antibody (1:1000), which was generated against human YAP (274-
454) (Howell et al., 2004). The blots were then probed with a secondary HRP conjugated 
anti-rabbit IgG antibody (1:10,000) (Jackson ImmunoResearch). The blots were incubated in 
stripping buffer (62.5 mM Tris, 2% SDS, 0.1 M β-mercaptoethanol, pH 6.7) and re-probed 
for elongation factor-2 (EF-2) using a goat anti-EF-2 antibody (1:500) (Santa Cruz) and a 
secondary HRP-conjugated anti-goat IgG antibody (1:4000) (Jackson ImmunoResearch). 
 
zYAP and embryo manipulations 
A Danio rerio full-length cDNA IMAGE clone 7066008 of yes-associated protein 65 
(zyap) (NM_001115121) was obtained from Open Biosystems. A zYAP MO (5’ CTC TTC 
TTT CTA TCC AAC TGA AAC C 3’) was designed to the 5’ UTR of zyap (Figure 1, 
GeneTools). In vitro translation reactions were performed using the TnT Quick Coupled 
Transcription/Translation System (Promega), according to the manufacturer’s protocol.  
1-cell embryos were injected with 16 ng of the zYAP MO, a standard control MO 
(GeneTools), or 300 or 600 pg of in vitro-transcribed ha-zyap mRNA. Once embryos reached 
the 1000-2000-cell stage, their chorion membranes were removed and embryos were placed 
on a custom fitted imaging mold (kindly supplied by Dr. Sean Megason) (Megason, 2009) 
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for time-lapse videography. Embryos were subsequently allowed to progress to the prim-11 
stage and fixed. 
 
qPCR 
 Xenopus laevis embryos were injected with 80 ng of the translational blocking xYAP 
MO cocktail or a control MO at the 1-cell stage. When sibling control embryos reached stage 
11, total RNA was isolated using the Trizol reagent (Invitrogen), according to the 
manufacturer’s protocol. RNA was quantified using a RiboGreen RNA quantitation kit 
(Invitrogen), according to the manufacturer’s instructions. Total RNA (2 µg) was reverse 
transcribed using Vilo cDNA synthesis (Invitrogen), according to the manufacturer’s 
protocol. Then, qPCR was performed on a 7900HT 380-well block Real-Time PCR system 
(Applied Biosystems) using Maxima SYBR green qPCR master mix (Fermentas) on serial 
dilutions of the RT product to ensure the efficiency of amplification with each primer set was 
within 10% of one another. A relative quantification study was performed using 5 µL of a 
1:100 dilution of the RT product, which was amplified using gene-specific primers: 
brachyury (Forward: 5’ TCT CTT TCA CAT GCT GTG CC 3’, Reverse: 5’ GTG CCG TGA 
CAT CAT ACT GG 3’); goosecoid (Forward: 5’ CAC ACA AAG TCG CAG AGT CTC 3’, 
Reverse: 5’ GGA GAG CAG AAG TTG GGG CCA 3’); wnt8 (Forward: 5’ TAT CTG GAA 
GTT GCA GCA TAC A 3’, Reverse: 5’ GCA GGC ACT CTC GTC CCT CTG T 3’); nodal-
related 3 (nr3) (Forward: 5’ CGA GTG CAA GAA GGT GGA CA 3’, Reverse: 5’ ATC 
TTC ATG GGG ACA CAG GA 3’); siamois (Forward: 5’ AAG ATA ACT GGC ATT CCT 
GAG C 3’, Reverse:  5’ GGT AGG GCT GTG TAT TTG AAG G 3’); sox17α (Forward: 5’ 
GCA AGA TGC TTG GCA AGT CG 3’, Reverse: 5’ GCT GAA GTT CTC TAG ACA CA 
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3’); sox11 (Forward: 5’ GGC TCT GGA TGA GAG TGA CC 3’, Reverse: 5’ TGA TGA 
AGG GGA TTT TCT CG 3’); h4 (Forward: 5’ GGG ATA ACA TTC AGG GTA TC 3’, 
Reverse: 5’ CAT GGC GGT AAC TGT CTT C 3’) 
 
In situ hybridization and β-galactosidase staining 
Xenopus laevis embryos were fixed in MEMFA, stained for expression of a NLS-β-
galactosidase lineage tracer, and processed for whole mount in situ hybridization according 
to standard protocols (Harland, 1991, Sive et al., 2000). Anti-sense DIG-labeled RNA probes 
were synthesized from the following plasmids: chordin (EcoRI, T7) (Sasai, Y. et al., 1994), 
eomesodermin (XhoI, T7) (Ryan et al., 1996), brachyury (ClaI, T7) (Smith et al., 1991), 
vent2 (EcoRI, T7) (Ladher et al., 1996), not (HindIII, T7) (von Dassow et al., 1993), sox2 
(HindIII, T7) (Lu et al., 2004), neuroD (XhoI, T3) (Lee, J. E. et al., 1995), n-tubulin (BamHI, 
T3) (Chitnis et al., 1995), p27Xic1 (BamHI, T7) (Hardcastle et al., 2000), sox11 (SalI, T3) 
(Hiraoka et al., 1997), six1 (NotI, T7) (Pandur et al., 2000), notch (ClaI, Sp6) (Coffman, C. 
R. et al., 1993), hes1 (SalI, T7) (Open Biosystems, BC070988), zic1 (EcoRI, T3) (Mizuseki 
et al., 1998), foxD3 (BamHI, T3) (Sasai, N. et al., 2001), and pax3  (SalI, T7) (Lu et al., 
2004). A full-length probe for myoD was PCR amplified from a Xenopus laevis (stage 19-26) 
cDNA library, which was kindly provided by Dr. Aaron Zorn, using the following primers: 
forward (GGA CTA GTA TGG AGC TGT TGC CCC CAC CAC TG) and reverse (CGG 
AAT TCC TAT AAG ACG TGA TAG ATG GTG CTG), and subcloned into the pBluescript 
SK(-) vector at the SpeI and EcoRI sites. This myoD probe was then synthesized as described 
above (SpeI, T7). 
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Chromatin Immunoprecipitation (ChIP) 
ChIP assays were performed with the ChIP-IT Express kit (Active Motif) with some 
modifications. Three hundred stage 14-16 Xenopus laevis embryos were incubated, with 
gentle rolling, in 10 ml of 1% formaldehyde/0.1X modified Barth’s solution (MBS) for 30 
minutes at room temperature to crosslink genomic DNA and protein complexes. Crosslinking 
was stopped by incubating the embryos in 125 mM glycine/0.1X MBS with gentle rolling. 
Following two washes in 0.1X MBS, the embryos were snap-frozen and stored at -80°C. 
Chromatin was sheared with a Misonix 3000 cup horn by repeating 6 cycles of 30sec: 1sec 
pulse, 0.5 sec off at a power of 5. Samples rested on ice for 1 minute between each cycle. 
Shearing efficiency was determined by resolving a reverse-crosslinked, precipitated sample 
of chromatin on a 1% agarose gel. This sample was quantified using a Nanodrop, and 12.5 or 
25 µg of chromatin was subsequently immunoprecipitated for 4 hours with 2 mg of affinity-
purified YAP antibody or rabbit IgG (Genscript) in the presence of 0.25mg/ml BSA and 0.1 
mg/ml herring sperm DNA. Beads were washed once with ChIP buffer 1 (Active Motif) and 
twice with ChIP buffer 2 (Active Motif) prior to elution and proteinase K treatment. Five 
percent of the eluate was used to amplify the pax3 promoter TEAD-binding site region using 
the following xpax3-specific primers: forward (GCC TGA CAA TGG CAC CTT AT) and 
reverse (AGG CGC ACT TGT GTG ATT C). For subcloning this region, a proofreading 
DNA polymerase (cloned Pfu DNA polymerase, Stratagene) was used to PCR amplify the 
product from the isolated YAP co-immunoprecipitated Xenopus laevis genomic DNA. This 
PCR product was then gel-purified from a 1% agarose gel. Alanines were then added back to 
the ends using a non-proofreading DNA polymerase (Jumpstart Taq polymerase, Sigma-
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Aldrich). The products were then ligated into the pCRII-TOPO vector (Invitrogen) and 
sequenced. 
 
Luciferase Assays 
The 5’-flanking transcriptional regulatory region for pax3 was amplified by PCR 
from Xenopus laevis genomic DNA using forward (5’ GCC TGA CAA TGG CAC CTT AT 
3’) and reverse primers (TCC TGC CTC GGA GGT AAC TAG TG) and subcloned into the 
KpnI and EcoRV sites of the pGL4.10 luciferase vector (Promega). A three-base mutation of 
the putative xTEAD1-binding site within this 5’-flanking region was performed using a 
forward primer (CTG GCC ACT GCT ATA AGG TAC TTT CAA CAA ATG C) and a 
reverse primer (GCA TTT GTT GAA AGT ACC TTA TAG CAG TGG CCA G) and the 
Quikchange II Site-Directed Mutagenesis Kit (Stratagene). In vitro-fertilized Xenopus laevis 
embryos were co-injected with a β-galactosidase (β-gal) reporter under the control of the 
actin promoter in combination with the pGL4.10, pGL4.10-pax3, or pGL4.10-pax3-Mut with 
or without the addition of 100 ng of xtead1 and xyap. Each sample (n) consisted of fifteen, 
pooled, stage 14-16, embryos, which were collected, lysed in 150 µL Glo Lysis Buffer 
(Promega), and snap-frozen in an ethanol-dry ice bath. Upon thawing, an equal volume of 
Freon (1,1,2-trichlorotrifluoroethane, Sigma) was added to each sample, spun at 13000 x g 
for 15 minutes at 4°C, and transferred to a new tube.  Luciferase activity was measured by 
combining 50 µL of embryo lystates with 50 µL of the Steady-Glo luciferase assay substrate 
(Promega). Samples were then gently rotated for 5 minutes at room temperature, and the 
activity was detected with a Victor luminometer (PerkinElmer). β-gal activity was measured 
using 10 µL of the embryo lysate in 67 µL of sodium phosphate buffer (0.1 M, pH 7.5), 1 µL 
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of 100X Mg2+ solution (0.1 M MgCl2, 4.5 M β-mercaptoethanol), and 22 µL of 1X ONPG 
(Sigma) in sodium phosphate buffer (Sambrook and Russell, 2001). The reaction was carried 
out in a 37°C incubator for 1 hour and stopped by the addition of 167 µL of 1 M sodium 
carbonate. β-gal activity was determined by measuring the level of the hydrolysis product of 
1X ONPG at a wavelength of 405 nm (Victor microplate reader, PerkinElmer). The 
luciferase activity was normalized according to the β-gal activity by taking the ratio of 
luciferase activity to β-gal expression in the embryos. 
Similarly, 100 pg of TOPflash (Clontech), a Wnt luciferase reporter containing TCF- 
binding sites or FOPflash (Clontech), a luciferase reporter with these TCF sites mutated, 
were co-injected with 100 pg of a β-gal reporter, alone or in the presence of 1 ng RNA 
encoding for HA-xYAP or HA-xYAP ΔC-term into in vitro-fertilized 1-cell Xenopus laevis 
embryos. Sample collection, preparation, and analyses were performed as described above. 
 
Results 
We previously showed that YAP-/- mice were embryonic lethal and exhibited severe 
developmental abnormalities that included defects in yolk sac vasculogenesis, chorioallantoic 
fusion, and A-P axis elongation (Morin-Kensicki et al., 2006). Given that these defects could 
be due to nutritional deficiencies, we sought to better characterize a role for YAP during 
early development by using Xenopus laevis and Danio rerio, animal models for which the 
nutritional needs of the embryos are self-contained. In addition, these embryos permit easy 
knockdown of targeted protein expression via injection of gene-specific MOs and efficient 
gain-of-function assessment via mRNA injections.  
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YAP is required for progression through gastrulation. 
The full-length Xenopus laevis yap (xyap) EST encodes a protein that is 78% 
identical to mouse YAP and contains all the described protein-protein interaction domains, as 
well as the transcriptional activation domain (Figure 1). Isolation of Xenopus laevis genomic 
DNA and subsequent PCR validated that our RT-PCR primer design amplified a PCR 
product across exon-intron boundaries (Figure 2). RT-PCR and western blot analyses 
revealed that xyap mRNA and protein are maternally expressed in an unfertilized egg and 
persists throughout Xenopus laevis tadpole stages (Figure 3), which is consistent with results 
from mouse and Xenopus tropicalis (Morin-Kensicki et al., 2006, Nejigane et al., 2011, 
Sawada et al., 2005). Four xYAP MOs were designed around the translational start site 
(Figure 1) and the efficacies of three of them (MO1, MO2, and MO3) were confirmed in 
vitro (Figure 4). An antibody directed against the C-terminus (274-454) of human YAP 
(hYAP) detected a band at the appropriate size from cold in vitro-translated xYAP product 
and stage 15 whole embryo lysates (Figure 5). We used this hYAP antibody to test the 
efficacy of our xYAP MOs in vivo. Lysates from stage 15 MO-injected embryos showed 
efficient knockdown of endogenous xYAP expression to undetectable levels (Figure 6).  
In vitro-fertilized sibling Xenopus laevis embryos that were injected with 80 ng of 
any one of these xYAP MOs at the 1-cell stage failed to complete epiboly and close the 
blastopore (MO1, n=200, 100%; MO2, n=185, 100%; MO3, n=191, 100%), while uninjected 
(n=349) and control MO-injected (n=231) embryos progressed through gastrulation 
unexpurgated (Figure 7). Furthermore, these xYAP MO-injected embryos arrested at the 
open-blastopore stages. The same effect was observed using 40 ng (n=725, 100%) and 80 ng 
(n=352, 100%) of an equimolar cocktail of all three translation-blocking MOs injected into 
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Figure 2: Validity of xYAP RT-PCR primer design. The proper design of the xYAP RT 
primers was confirmed by amplification of a larger, 2200 base pair, PCR product from 
isolated Xenopus laevis genomic DNA compared to the amplification of a 305 base pair PCR 
product from a xYAP cDNA.  
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Figure 3: mRNA and protein expression of xYAP during Xenopus laevis development. 
RT-PCR analyses showed that xyap RNA was maternally expressed in an unfertilized egg 
and early cleavage (stage 3), decreases slightly between late cleavage (stage 6) and the mid-
blastula transition (stage 9), but was then expressed abundantly through subsequent stages of 
Xenopus laevis development through feeding tadpole (stage 40). The (+) indicates lanes that 
included reverse transcriptase in the RT-PCR reaction, while the (-) indicates lanes that 
lacked the reverse transcriptase in the RT-PCR reaction. Western blot analysis showed that 
xYAP protein was maternally present at cleavage stages (stages 2-7), was detectable at the 
onset of epiboly and gastrulation (stages 9-10), and increased dramatically from mid-gastrula 
(stage 11) onwards. The (+) represents the positive control lane, which contains a cold in 
vitro translated xYAP product.  
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Figure 4: Efficacy of xYAP-MOs in vitro. xyap mRNA was in vitro translated with or 
without the presence of four MOs designed to target the 5’ UTR of xyap. All in vitro 
translations were performed in the presence of [35S]methionine and proteins were visualized 
by phosphoimage analysis. MO1, MO2, and MO3 efficiently knocked down xYAP protein 
expression in vitro, whereas a fourth (-) did not. 
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Figure 5: hYAP antibody recognized Xenopus laevis YAP. A rabbit polyclonal antibody, 
generated against the C-terminus of human YAP, specifically recognized in vitro translated 
xYAP (+DNA), but not the mock translated control (-DNA). Similarly, the antibody 
recognized a single protein in stage 15 Xenopus laevis whole embryo lysates. 
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Figure 6: Efficacy of xYAP-MOs in vivo. Injection of an equimolar cocktail of xYAP MO1, 
MO2, and MO3 at two concentrations (40 ng and 80 ng) resulted in efficient knockdown of 
endogenous xYAP protein in stage 15 embryos as measured by western blot analysis. EF-2 
expression from the same blot served as the loading control.  
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Figure 7: Phenotype resulting from the individual xYAP MOs. Uninjected (UN) and 
control MO injected (cMO) embryos have closed blastopores (arrows) at the end of 
gastrulation. Sibling embryos injected with one of the three different xYAP MOs (80 ng; see 
Figure 1 for binding sites) resulted in failure to close the blastopore (arrows) at the same 
developmental time. 
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1-cell embryos (Figure 8), into one blastomere of 2-cell embryos (Figure 9), or with xYAP 
splice MOs targeted to exon 1 (n=328, 76%) and exon 2 (n=131, 77%) (not shown). The 
phenotype associated with the xYAP splice MOs likely was not as robust because they were 
less efficient at knocking down endogenous protein expression (Figure 10). Together, these 
results demonstrate the specificity of the xYAP MOs. 
Reducing the concentration of the xYAP MO cocktail allowed blastopore closure, but 
resulted in dose dependent A-P axis elongation defects (Figure 11).  Embryos injected with 
1.25 ng (n=113) or 2.5 ng (n=142) of the xYAP translation blocking MO cocktail appeared 
unaffected, whereas embryos injected with 5-20 ng (5 ng, n=152; 10 ng, n=155; 20 ng, 
n=163) of this cocktail did not progress through gastrulation as rapidly as their control 
siblings, which resulted in shortened body axes (Figure 11). 
Although the defective blastopore closure phenotype was reproducible using three 
different translational blocking xYAP MOs individually or in combination as well as two 
different splice blocking xYAP MOs, the phenotype was not rescued by co-injecting 2 ng of 
frog (xyap), mouse (myap), or human (hyap) mRNAs (not shown), even though they all were 
properly translated in Xenopus laevis embryos (Figure 12C). This result suggested that xYAP 
gain-of-function may also have an adverse effect on developmental progression, as reported 
for other scaffolding proteins (Lee, H. S. et al., 2008). Interestingly, 0.25, 0.5, 1, and 2 ng of 
xyap mRNA injected into 1-cell embryos did not cause observable blastopore closure defects 
or observable morphological alterations until the tadpole stage (Figure 12B). In fact, all three 
mRNAs produced similar morphological alterations in the elongation of the A-P axis (Figure 
12B), suggesting conservation of function. Therefore, we tested whether knockdown of YAP 
in another animal model, using similar methods, would produce a similar phenotype.  
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Figure 8: Phenotype resulting from a cocktail of the three xYAP MOs. In vivo 
knockdown of xYAP by injection of 40 ng of an equimolar the xYAP MO cocktail (green) 
into 1-cell Xenopus laevis embryos prevented the blastopore (arrow) from closing. Injections 
with an equal concentration of a control MO (red) allowed blastopore closure and had no 
other discernable effect on embryo development. 
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Figure 9: Phenotype resulting from injecting the xYAP MO cocktail into one cell of the 
2-cell embryo. In vivo knockdown of xYAP by injection of 40 ng of the xYAP MO cocktail 
(green) into one blastomere of the 2-cell Xenopus laevis embryo prevented the blastopore 
(arrow) from closing. Injections with an equal concentration of a control MO (red) allowed 
blastopore closure and had no other discernable effect on embryo development. 
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Figure 10: Efficacy of xYAP splice blocking MOs. Two different concentrations (40 ng 
and 80 ng) of xYAP splice blocking MOs (xYAP Exon 1 MO and xYAP Exon 2 MO) 
reduced endogenous xYAP protein compared to control MO injected embryos. However, 
they were less efficient than the MOs targeted to the translational start site (Figures 4 and 6).  
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Figure 11: Phenotype resulting from titration of xYAP MO concentrations. Reducing 
the concentration (1.25, 2.5, 5, 10, and 20 ng) of the xYAP MO cocktail (left side) allowed 
blastopore closure, but resulted in dose-dependent A-P axis shortening. Embryos are siblings 
collected at the same developmental time. 
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Figure 12: xYAP, mYAP, and hYAP gain-of-function in Xenopus laevis. (A) Western 
blot showing proper expression of increasing concentrations of HA-xYAP in stage 15 whole 
Xenopus laevis embryo lysates. (B) Frog (x), mouse (m), and human (h) YAP gain-of-
function in Xenopus laevis embryos all showed similar axial phenotypes. (C) Using 
antibodies against the HA tag (left) and YAP (right), western blots of stage 15 whole 
Xenopus laevis embryo lysates illustrated proper overexpression of xYAP, mYAP, and 
hYAP. 
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Injection of 16 ng of a zYAP MO into fertilized 1-cell zebrafish embryos resulted in delayed 
epiboly (Figure 13). Time-lapse videography showed that, in the absence of zYAP, 
developmental progression was perturbed beginning at 50% epiboly (5.25 hours post-
fertilization, hpf) compared to uninjected and control MO-injected embryos (Figure 14, n=15 
per each group).  Although we used a high concentration of the zYAP MO to determine the 
start of the YAP MO-mediated developmental delay, our results are consistent with another 
group that used lower MO concentrations to determine later developmental defects and yet 
still observed YAP MO-mediated developmental delays (Jiang, Q. et al., 2009). Thus, in 
three different vertebrates, loss of early YAP function interferes with the developmental 
networks that allow the embryo to progress through the process of gastrulation. 
To determine whether the MO-mediated gastrulation defects correlated with an effect 
on genes required for germ-layer formation, we performed qPCR analyses on well-
established markers of each germ layer.  Control MO (80 ng) or the xYAP MO cocktail (80 
ng) were injected into one-cell Xenopus laevis embryos, and the embryos were collected 
when uninjected siblings reached mid-gastrulation (stage 11), a stage when germ layer 
markers are abundantly expressed. Genes normally expressed in the organizer at the onset of 
gastrulation were either unaffected (siamois) or moderately increased (nodal-related 3). In 
contrast, the expression levels of endodermal (sox17, p<0.013), neural ectodermal (sox11, 
p<0.021), and three out of five mesodermal (brachyury, p<0.013; goosecoid, p<0.011; wnt8 
p<0.018) genes were significantly reduced in YAP MO-injected embryos (Figure 2A). 
However, analyses of several mesodermal markers by in situ hybridization in Xenopus laevis 
showed that these quantitative changes resulted from delayed expression rather than loss of 
mesoderm induction. While brachyury, eomesodermin, and chordin expression was markedly
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Figure 13: Phenotype resulting from zYAP MO. zYAP MO-injected embryos are delayed 
in development beginning at gastrulation, as evidenced by failure of the epiboly front (*) to 
surround the yolk plug as seen in the uninjected sibling controls. 
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Figure 14: Time-lapse video of 1-cell zYAP-MO injection. Time-lapse video microscopy 
showed that zYAP MO (16 ng) injected embryos exhibit delayed gastrulation. Asterisks 
mark the tissue front of epiboly movements. In uninjected and cMO-injected embryos, this 
front completely envelops the yolk by 10 hours post-fertilization (hpf). These fronts are still 
in the equatorial region in the 7.7-10 hpf YAP MO-injected embryos. 
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Figure 15: qPCR analysis of the expression of genes required for germ layer formation 
in Xenopus laevis. qPCR analysis of mRNA levels from uninjected, control MO-injected, 
and xYAP MO-injected Xenopus embryos collected when sibling controls reached stage 
10.5/11.  brachyury, goosecoid, wnt8, sox11, and sox17 mRNA levels were reduced, nodal-
related 3 mRNA levels were increased and siamois mRNA levels remained unchanged in 
xYAP morphant embryos. 
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reduced in xYAP MO-injected embryos compared to sibling stage 11 embryos (Figure 2B), 
at sibling stage 13 these genes, as well as several others, were expressed in patterns similar to 
control stage 11 embryos (Figure 16, n=14-25 per sample, 100% for all markers). Thus, 
eliminating endogenous xYAP protein does not prevent mesodermal gene induction, but does 
delay the expression of a number of mesodermal genes. These results indicate that the failure 
to progress through gastrulation in the absence of YAP is due to some developmental process 
other than germ layer induction. 
 
YAP gain-of-function also causes axis elongation defects 
From these results, we predicted that increasing YAP protein above endogenous 
levels may cause gastrulation to be completed more rapidly. However, time-lapse video 
recordings of gastrulation movements in zebrafish embryos injected with 2 different doses of 
zyap mRNA did not detect any differences in the amount of time required for epiboly 
movements to close around the yolk plug (Figure 17; n=5 per group). When these zyap 
mRNA injected embryos developed to later stages, however, significant perturbations were 
observed (Figure 18; 300 pg, n=111, 100%; 600 pg, n=94; 100%), including shortened and  
malformed body axes and perturbed somitic, eye, and head morphologies. Likewise, 
injection of xyap, myap, or hyap (2 ng) mRNAs all caused similar phenotypes in Xenopus 
laevis embryos (Figure 12B; n=155 (xyap), n=102 (myap), n=93 (hyap), 100% affected). 
Because YAP gain-of-function experiments produced a shortened and malformed body axis, 
we tested whether there was a defect in somite formation. Whole embryo immunostaining for 
Tropomyosin, a marker of cardiac and skeletal muscle, revealed that somites in xyap-injected 
Xenopus laevis embyos lost their typical chevron shape but instead exhibited an ill-defined, 
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Figure 16:  In situ characterization of xYAP morphants. In situ characterization of gene 
expression in uninjected, control MO-, and xYAP MO-injected Xenopus embryos. Controls 
and sibling age-matched injected embryos are at the equivalent of stage 11 on the left and of 
stage 13 on the right. xYAP morphant embryos express each gene in the correct location, but 
the spatial pattern resembles an earlier developmental stage. For example, brachyury 
expression in the stage 11 YAP MO embryo is only faintly detected, but in the stage 13 YAP 
MO embryo it is indistinguishable from the control stage 11 pattern. chordin expression in 
the stage 11 YAP MO embryos is not detected, but in the stage 13 YAP MO embryo it 
remains confined to the dorsal blastopore lip (arrow), as in the controls at stage 11; it has not 
elongated along the A-P axis as in the stage 13 controls.  eomesodermin expression in the 
stage 11 YAP MO embryo remains on the surface in the uninvoluted mesoderm (arrow), 
whereas in controls, eomesodermin-expressing cells have migrated internally (Ryan et al., 
1996). For vent2, myoD, and not, the stage 13 expression patterns are consistent with 
published patterns of early gastrulation stages, indicating developmental delay rather than 
loss of mesoderm. In the stage 11 panel, all views are vegetal; in the stage 13 panel, the 
views of brachyury and vent2 embryos and of the YAP MO chordin embryos are vegetal and 
the remainder are dorsal. 
 70 
 
  
 71 
Figure 17: Time-lapse video of epiboly progression in zyap mRNA injected Danio rerio 
embryos. Time-lapse videomicroscopy shows that zYAP gain-of-function does not alter the 
timing of gastrulation movements, as evidenced by in the progression of epiboly (asterisks 
mark the fronts of tissue movement around the yolk) after injection of two mRNA doses (300 
pg and 600 pg) of zyap mRNA. 
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Figure 18: Effects of zYAP gain-of-function in Danio rerio embryos. zYAP gain-of-
function in Danio rerio embryos resulted in head and eye deformities and shortened, 
malformed body axes. Examples of two different mRNA doses are shown. 
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curved shape (Figure 19). Nonetheless there were no obvious changes in the arrangement of 
the sarcomeres at the ultrastructural level (Figure 20). Given that YAP is a well-described 
transcriptional co-activator, we predicted that increasing YAP levels may alter the expression 
of genes involved in patterning and/or elongation of the A-P axis.  
 
YAP expands neural progenitors and inhibits neural differentiation 
Because vertebrate A-P axis elongation is accomplished in part by elongation of the 
neural plate (Keller et al., 2003, Wallingford et al., 2001), we investigated whether neural 
progenitor fields were altered in YAP gain-of-function Xenopus laevis embryos. Given that 
our previous YAP gain-of-function experiments were injected into one-cell Xenopus laevis 
embryos, we chose to more closely monitor where our injected mRNA ended up in the 
embryo by co-injecting xyap and β-galatosidase (β-gal; as a lineage tracer) mRNAs into one 
blastomere of the 2-cell embryo. The neural progenitor field, indicated by sox2 expression, 
was expanded as evidenced by a darker, longer, and/or wider expression domain compared to 
the uninjected side of the same embryo (Figure 21A). Consistent with this result, injection of 
the YAP MO cocktail (40 ng) caused a loss of sox2 expression on the injected side (Figure 
21A). YAP gain-of-function caused a concomitant reduction of neural differentiation marker 
expression (Figure 21B). neuroD, a bHLH neural differentiation transcription factor,  p27Xic1, 
a cdk inhibitor shown to be important for cell cycle exit and subsequent neural differentiation 
(Hardcastle et al., 2000), and n-tubulin, a post-mitotic neuronal marker, each were strongly 
repressed (Figure 21B). Interestingly, the expression of a muscle-specific bHLH 
differentiation marker, myoD, also was strongly repressed (Figure 21D). It is well 
documented that increased Notch expression and/or signaling correlates with increased
 76 
Figure 19: Altered Tropomyosin staining in xYAP gain-of-function Xenopus laevis 
embryos. Whole embryo immunostaining for Tropomyosin, a marker of cardiac and skeletal 
muscle, revealed that somites in xyap-injected Xenopus laevis embyos exhibited an ill-
defined, curved shape, rather than the typical chevron shape seen in uninjected embryos. 
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Figure 20: TEM analysis of somitic muscle in xYAP gain-of-function Xenopus laevis 
embryos. Transmission electron micrographs of skeletal muscle taken from control and 
xyap-injected Xenopus laevis embyos (stage 30) exhibited no obvious changes in the 
arrangement and makeup of the sarcomeres (arrows), which run from one Z line to the next.  
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Figure 21: xYAP gain-of-function expands neural progenitor fields, while neural 
differentiation is inhibited. (A) The neural plate progenitor field marked by sox2 expression 
(blue stain) was darker, longer, and/or wider on the xyap-injected side (arrow, red β-gal 
staining) compared to the uninjected side of the same embryo.  xYAP MO-mediated 
knockdown (40 ng) eliminated sox2 expression on the injected side, whereas a control MO 
(cMO) did not. In this and all subsequent panels: n=sample size; %=frequency of the 
phenotype; arrow indicates injected side. (B) Expression of three genes indicative of neural 
differentiation (neuroD, n-tubulin, p27Xic1) were inhibited by xYAP gain-of-function. (C) 
xYAP gain-of-function reduced notch and hes1 expression. (D) Expression of myoD, a 
muscle differentiation marker, was reduced by xYAP gain-of-function. All views are dorsal-
anterior. 
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numbers of neural progenitors, decreased numbers of differentiated neurons (Coffman, C. et 
al., 1990, Coffman, C. R. et al., 1993, Taranova et al., 2006), and increased YAP expression 
(Camargo et al., 2007). Therefore, we were surprised to observe that xYAP gain-of-function 
reduced the mRNA levels of notch and hes1, a direct Notch signaling target gene (Jarriault et 
al., 1995, Jarriault et al., 1998, Kuroda et al., 1999) (Figure 21C). These results indicate that 
YAP’s ability to repress neural differentiation is likely independent of Notch signaling. 
The expansion of neural progenitors by increased YAP levels also reduced the 
expression domain of the differentiated epidermis, as marked by an epidermal-specific cyto-
keratin (Jonas et al., 1985) (Figure 22B). Because interactions between the neural plate and 
the epidermis lead to the formation of a neural plate border zone that gives rise to the 
precursors of the peripheral nervous system, the pre-placodal ectoderm (PPE), and the neural 
crest (Schlosser, 2006), we analyzed whether these tissues were properly formed. In fact, the 
expression of two PPE genes (six1; sox11; Brugmann et al., 2004) and two genes that are 
expressed by premigratory neural crest (foxD3; zic1) were dramatically reduced (Figure 22A, 
B). In addition, the pax3+ precursors of the hatching gland were virtually eliminated (Figure 
22D). Thus, in xyap-injected embryos there was a failure to form three different precursor 
populations that contribute to the formation of peripheral cranial structures. The perturbations 
in these three embryonic cell populations likely account for the severe defects in head 
morphology seen in the YAP gain-of-function tadpoles (Figure 12B).  
 
YAP cooperates with TEAD to expand pax3+ neural crest progenitors 
While the pax3+ hatching gland progenitor cells were virtually eliminated, pax3 
expression in the neural plate border zone that is required for neural crest specification 
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Figure 22: xYAP gain-of-function inhibits the expression of genes in the pre-placodal 
ectoderm, epidermis, pre-migratory neural crest and hatching gland. (A) The expression 
of genes in the pre-placodal ectoderm (PPE), sox11 and six1, are dramatically reduced on the 
xyap-injected sides. Brackets indicate the laterally located PPE expression domains on both 
sides the embryos. Anterior views. (B) Expression of the epidermis-specific cyto-keratin 
gene is lost on the xyap-injected side. Anterior view. (C) The expression of genes 
characteristic of premigratory neural crest (foxD3, zic1 at bracket) are repressed on the xyap-
injected sides. Anterior-dorsal views. (D) pax3 expression in the surface ectodermal A-P 
stripe, which indicates the hatching gland progenitors (vertical arrows) is repressed on the 
xyap-injected side. In contrast, pax3 expression in the underlying neural crest progenitors is 
expanded (see Figure 23). Dorsal view.   
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(Monsoro-Burq et al., 2005) was extended, broadened, and/or stronger compared to the 
uninjected, control side of the embryo (Figures 22D and 23A). This expansion of the pax3+ 
neural crest progenitor field was concomitant with a decrease in genes expressed by specified 
neural crest (zic1, foxD3; Figure 22C), suggesting that increased YAP holds these cells in a 
progenitor-like, undifferentiated state. Consistent with these gain-of-function results, 
embryos that were injected with the xYAP MO cocktail (40 ng) exhibited a complete loss of 
pax3 expression in both neural crest and hatching gland progenitors (Figure 23B). The loss of 
pax3 in the neural crest progenitors, but not in the hatching gland precursors, could be 
rescued with xyap mRNA (Figure 23B). 
Much of the in vivo transcriptional co-activator activity of YAP results from 
interactions with members of the TEAD transcription factor family (Li, Z. et al., 2010). 
Recently, Naye et al. (2007) characterized two Xenopus TEADs, xtead1 (xn-tef) and xtead3 
(xd-tef). Injection of xtead1 (100 pg) mRNA alone expanded the pax3+ neural crest 
progenitors, while a low dose of xyap (100 pg) mRNA alone had little effect (Figure 23C). 
However, upon co-injection of equal amounts of xtead1 (100 pg) and xyap (100 pg) mRNAs, 
the percentage of embryos with an expanded domain of pax3+ neural crest progenitors was 
greatly increased (Figure 23C), indicating cooperativity between these proteins. Although 
TEAD gain-of-function alone expanded the pax3+ neural crest progenitors, the above 
experiments show that YAP enhances this effect, and the YAP MO experiments indicate that 
YAP is required for this effect. Therefore, we predicted that YAP acts as a transcriptional co-
factor with xTEAD1 in regulating pax3 expression.  
Results from a series of pax3 promoter transgenic deletions led Milewski et al. (2004) 
to suggest that a TEAD-binding site within a neural crest enhancer region was responsible for 
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Figure 23: xYAP expands pax3-expressing neural crest progenitors. (A) The pax3-
expressing neural crest progenitor field (NCP) is darker, longer, and/or wider (bracket) on the 
xyap-injected side. Dorsal view, stage 15. (B) xYAP MO-mediated knockdown (40 ng) 
eliminated pax3 expression in both neural crest progenitors and hatching gland (HG) 
precursors. Addition of exogenous xyap (YAP MO + xyap) rescued pax3 expression in neural 
crest progenitors (NCP), but not in hatching gland. Dorsal views, stage 17. (C) tead1 mRNA 
injection (100pg) expands pax3-expressing neural crest progenitors (width of bar compared 
to control side) at a moderate frequency (see row labeled NCP above images). xyap mRNA 
injection (100pg) rarely expands this population. In combination (tead1/xyap, 100pg each), 
this population is expanded in nearly every embryo. The repression of the pax3-expressing 
hatching gland progenitors (see row labeled HG above images) also was greatest when 
TEAD/xYAP were co-expressed. Dorsal anterior views at stage 16.  
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neural crest expression of pax3. However, we failed to find conservation of this previously 
described TEAD-binding site in the Xenopus tropicalis genome (Figure 24A). Using the 
genomic alignment and conserved transcription factor binding site prediction program, 
ConTra (Hooghe et al., 2008), a predicted TEAD-binding site that was highly conserved in 
15 different vertebrates was identified 58 base pairs upstream of the previously described 
mouse neural crest enhancer TEAD2-binding site (Figure 24A). To demonstrate direct 
involvement of xYAP in the control of pax3 transcription, we performed a ChIP analysis of 
the xpax3 promoter from wild-type stage 14-16 Xenopus laevis embryo DNA that was 
sheared to an appropriate size (Figure 24B). Using primers made specifically to amplify the 
genomic region containing the conserved TEAD-binding site (yellow box in Figure 24A), 
endogenous xYAP co-immunoprecipitated with this region, illustrating the direct 
involvement of xYAP in regulating xpax3 transcription (Figure 24C). This TEAD binding 
site was specific since primers to another portion of the pax3 promoter were not pulled down 
with the YAP antibody (Figure 25A). Likewise, a region of the sox2 promoter, which 
possesses a putative TEAD binding site, also failed to be pulled down with the YAP antibody 
(Figure 25B). To confirm the presence of the TEAD-binding site within the YAP chromatin-
immunoprecipitated piece of Xenopus laevis genomic DNA, a proofreading Taq polymerase 
was used to amplify and subclone the product (Figure 24D). Interestingly, the conserved 
TEAD-binding site but not the proposed mouse TEAD2-binding site, was located in this 
amplified fragment (Figure 24D).  
To determine the functionality of this site, we subcloned this genomic region and a 
previously described three-base pair mutant (wild type: AAATTCCT, mutant: 
AAGGTACT) of the putative TEAD-binding site (Figure 24A) into a luciferase reporter and  
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Figure 24: Endogenous xYAP resides at a novel 5’ regulatory region of pax3. (A) A 
highly conserved putative TEAD-binding site (yellow boxes) is present in the 5’ regulatory 
region of the pax3 gene in 15 different vertebrates. A previously described mouse TEAD- 
binding site (red box) appears less conserved. (B) Chromatin isolated from 300 wild type 
stage 14-16 Xenopus laevis embryos was sheared to a size range of 150 to 900 base pairs. (C) 
Chromatin immunoprecipitations (ChIPs) from 12.5 µg or 25 µg of sheared chromatin 
immunoprecipitated a band at the expected size for the putative novel TEAD-binding site 
region with the hYAP antibody but not with a control IgG antibody. (D) Sequencing of this 
band from three different clones verified that the genomic region pulled down by the hYAP 
antibody contained the novel TEAD-binding site (yellow) when compared to the Xenopus 
tropicalis genomic sequence. 
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Figure 25: YAP does not co-immunoprecipitate with two other regions of Xenopus 
laevis genomic DNA. (A) Another region of the pax3 promoter, not containing putative 
TEAD binding sequences, failed to co-immunoprecipitate with YAP or the control IgG, yet a 
band of the expected size was amplified in the input lane. (B) A region of the sox2 promoter, 
containing a putative TEAD binding site, did not co-immunoprecipitate with YAP or the 
control IgG, yet a band of the expected size was amplified in the input lane. The positive 
control for the co-immunoprecipitation is shown in Figure 24C. 
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with or without xTEAD1 and xYAP mRNAs into 1-cell Xenopus laevis embryos.  These 
injected embryos (stage 14-16) were then collected and harvested for subsequent luciferase 
and β-gal assays. Results from these assays revealed that while the wild-type pax3 5’-
flanking region clearly produced strong luciferase activity (35-fold greater than control) and 
mutation of the TEAD-binding site only slightly reduced the luciferase activity (32-fold 
greater than control), the addition of 100 pg of xtead1 and xyap mRNAs strongly inhibited 
both luciferase activities (25-fold greater than control for the wild-type pax3 5’-flanking 
region and 7-fold greater than control for the TEAD-binding site mutation) (Figure 26). 
Although mutation of the TEAD-binding site did present a slight repression of luciferase 
activity, repression of the activity with the addition of xTEAD1 and xYAP was surprising, 
although similar effects on luciferase assays have been reported (Vassilev et al., 2001) and 
observed by us for other putative TEAD/YAP target promoters when TEADs and YAP are 
added into the system. Thus, it is likely that xTEAD1 and xYAP are not the only proteins 
that drive pax3 expression. Because YAP is a multifunctional protein, it may require multiple 
interactions for its role in regulating pax3 transcription. 
 
PDZ-binding motif of xYAP plays a role in epidermal and muscle differentiation 
To better define which protein-protein interaction domain of xYAP is responsible for 
the expansion of the neural plate and neural crest progenitors as well as the correlative 
inhibition of neural, epidermal, and somitic muscle differentiation, we performed a series of 
structure-function analyses whereby mutant forms of xYAP (Figure 27) were expressed on 
one side of the embryo (Table 1). Using the constitutively active form of xYAP (cActive 
xYAP) in which the LATS phosphorylation site was mutated, we confirmed that this nuclear
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Figure 26: Luciferase assay of the pax3 5’ regulatory region. Luciferase reporter 
constructs containing either the wild type pax3 5’ regulatory region or a mutation of the 
TEAD-binding site and a β-gal reporter with or without xTEAD1 and xYAP mRNAs were 
injected into 1-cell Xenopus laevis embryos, harvested at stage 14-16, and assayed for 
luciferase and β-gal activity. These assays revealed that the wild type pax3 5’-flanking region 
(pax3 promoter) produced strong luciferase activity (35 fold activity above control), while 
the TEAD-binding site mutation (Mut pax3 promoter) was only slightly reduced (32 fold 
activity above control). Furthermore, the addition of 100 pg of xtead1 and xyap mRNAs 
strongly inhibited luciferase activities for both the wild type and TEAD-binding mutant 
reporter constructs (25 fold above control for the wild type pax3 5’-flanking region and 7 
fold above control for the TEAD-binding site mutation).  
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Figure 27: xYAP mutants used for experiments listed in Table 1. Cartoons of the xYAP 
mutants created to determine which protein-protein interaction domain(s) is important for the 
in vivo gain-of-function phenotypes described in Figures 21-23. Deletions or mutations are 
indicated by color loss: the TEAD-binding site (xYAPΔTBS, purple), the LATS 
phosphorylation site (cActive xYAP, orange), the two WW domains (xYAPΔWW, red), the 
N-terminus (xYAP, ΔN-term) containing both the hnRNP U and TEAD binding sites, and the 
PDZ-binding motif (xYAPΔC-term, fuchsia) at the C-terminus. 
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localized form of xYAP caused expansion of neural plate (sox2) and neural crest (pax3) 
progenitors and reduction of pax3+ hatching gland precursors at frequencies comparable to 
wild type xYAP (Figure 28A, B). In contrast, deletion of the TEAD-binding site (TBS), WW 
domains, N-terminus, or C-terminus each resulted in a dramatic (sox2) to moderate (pax3-
NCP, pax3-HG) reduction in the frequency of the respective phenotypes, indicating that an 
intact protein is required. These results implicate multiple binding partners. In contrast, loss 
of neural plate differentiation (p27xic1) and the PPE (sox11) were maintained at high 
frequencies with each xYAP mutant, indicating that interactions at one or more of the 
remaining domains are sufficient to downregulate these genes. Interestingly, xYAP-mediated 
loss of somitic muscle (myoD) and epidermal (cyto-keratin) differentiation was specifically 
reduced by deletion of its PDZ-binding motif. These results implicate the involvement of a 
PDZ-containing interacting protein in the effects on these two tissues. The requirements for 
different YAP domains for the effects on these diverse embryonic tissues indicate that 
different binding partners are likely to mediate them. 
 
Discussion 
YAP is well conserved 
Through evolution, proteins within the WW domain-containing family have 
functionally diversified. Although no YAP homologue exists in yeast, the closest YAP 
relative, Rsp5, is a WW-containing protein exhibiting ubiquitin ligase activity. The 
Drosophila YAP homologue, Yorkie, exhibits little sequence conservation when aligned with 
its vertebrate YAP counterparts, especially at its C-terminal end where this protein lacks the 
conserved vertebrate transcriptional activation domain and the SH3- and PDZ-binding
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Figure 28: Bar graphs for data listed in Table 1. (A) The percentage of embryos showing 
expansion of sox2-expressing neural plate cells or expansion of pax3-expressing neural crest 
progenitor (NCP) cells after injection of each mutant form of xYAP. Note that cActive 
xYAP, which prevents YAP from leaving the nucleus, is as effective as wild type YAP. 
However, all other mutant forms reduce these phenotypes. Sample sizes are presented in 
Table 1. (B) The percentage of embryos showing reduced gene expression after injection of 
each mutant form of xYAP. Deletion of the WW domains or of the PDZ-binding motif 
interfered the most with repression of pax3+ hatching gland (HG) progenitors. Loss of neural 
plate differentiation (p27xic1) and a PPE marker (sox11) were maintained at high frequencies 
with each xYAP mutant, indicating that interactions at one or more of the remaining domains 
are sufficient to downregulate these genes. However, xYAP-mediated loss of somitic muscle 
(myoD) and epidermal (cyto-keratin) differentiation was specifically reduced by deletion of 
its PDZ-binding motif. 
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Table 1: PDZ-binding motif of xYAP plays a role in epidermal and muscle 
differentiation. Sample sizes and frequencies of genes that were expanded (sox2, pax3+ 
neural crest progenitors [NCP]) or reduced (pax3+ hatching gland [HG] progenitors, p27xic1, 
sox11, myoD, and cyto-keratin) after injection of wild type xyap or mutant (defined in Figure 
27) xyap mRNAs. 
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Probe RNA Injected % Change 
sox2 xYAP n=22, 73% expanded 
sox2 cActive xYAP n-20, 85% expanded 
sox2 xYAP Δ TBS n=42, 19% expanded 
sox2 xYAP Δ WW n=62, 11% expanded 
sox2 xYAP Δ N-term n=18, 0% expanded 
   
pax3 (NCP) xYAP n=51, 65% expanded 
pax3 (NCP) cActive xYAP n=19, 74% expanded 
pax3 (NCP) xYAP Δ TBS n=68, 48% expanded 
pax3 (NCP) xYAP Δ WW n=64, 45% expanded 
pax3 (NCP) xYAP Δ N-term n=16, 50% expanded 
pax3 (NCP) xYAP Δ C-term n=18, 38% expanded 
   
pax3 (HG) xYAP n=41, 90% reduced 
pax3 (HG) cActive xYAP n=17, 76% reduced 
pax3 (HG) xYAP Δ TBS n=68, 83% reduced 
pax3 (HG) xYAP Δ WW n=67, 54% reduced 
pax3 (HG) xYAP Δ N-term n=8, 100% reduced 
pax3 (HG) xYAP Δ C-term n=13, 54% reduced 
   
p27xic1 xYAP n=25, 98% reduced 
p27xic1 xYAP Δ TBS n=35, 83% reduced 
p27xic1 xYAP Δ WW n=42, 79% reduced 
p27xic1 xYAP Δ N-term n=35, 69% reduced 
p27xic1 xYAP Δ C-term n=35, 69% reduced 
   
sox11 xYAP n=35, 89% reduced 
sox11 xYAP Δ TBS n=31, 90% reduced 
sox11 xYAP Δ WW n=33, 82% reduced 
sox11 xYAP Δ N-term n=34, 94% reduced 
sox11 xYAP Δ C-term n=35, 91% reduced 
   
myoD xYAP n=52, 68% reduced 
myoD xYAP Δ TBS n=34, 100% reduced 
myoD xYAP Δ WW n=81, 80% reduced 
myoD xYAP Δ N-term n=71, 58% reduced 
myoD xYAP Δ C-term n=50, 19% reduced 
   
cyto-keratin xYAP n=32, 100% reduced 
cyto-keratin xYAP Δ TBS n=42, 100% reduced 
cyto-keratin xYAP Δ WW n=47, 100% reduced 
cyto-keratin xYAP Δ N-term n=41, 100% reduced 
cyto-keratin xYAP Δ C-term n=38, 0.03% reduced 
 103 
motifs. However, other invertebrates, such as the acorn worm, honeybee, wasp, sea anemone, 
sea urchin, and sea squirt, which also exhibit low vertebrate YAP identity (~40%), do 
possess the PDZ-binding motif. In order to utilize frog and fish to elucidate a common 
functional role in vertebrate development, it is important to establish that the YAP proteins in 
these animals contain similar functional domains.  Indeed, xYAP and zYAP are 78% 
identical to the mouse homologue and contain all of the functional domains described in 
mammals. Interestingly, the proline-rich region present at the N-terminus of the human 
homologue, which allows for hnRNP U binding, contains fewer prolines in non-mammals 
(human, 18; mouse, 15; frog, 6; zebrafish, 3). 
The functional diversity of YAP in vivo, however, is just now beginning to be 
unraveled. In particular, there is a paucity of information regarding its function in early 
vertebrate developmental processes. Previously, we reported that mice lacking YAP exhibit 
severe developmental phenotypes that result in early lethality (Morin-Kensicki et al., 2006). 
Given that the A-P axis defects may result from the extra-embryonic tissue defects, we 
exploited two more amenable models, Xenopus laevis and Danio rerio, to investigate the 
function of YAP during early development. Herein, we provide the first description of the 
mechanism by which YAP regulates the completion of gastrulation and the elongation of the 
A-P body axis. This protein is required for the proper timing of expression of early 
mesodermal genes, and for the expansion of the sox2+ neural plate and pax3+ neural crest 
progenitors at the neural plate border. We demonstrate that the effects of YAP, a 
transcriptional co-activator, on pax3+ neural crest progenitors are accomplished, at least in 
part, by co-regulation of the pax3 gene via interaction with the transcription factor, TEAD1. 
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YAP is required for progression through gastrulation 
 The MO-mediated elimination of xYAP in vivo resulted in a failure of the embryo to 
close its blastopore, and while a hypomorphic knockdown allowed gastrulation to procede, 
these embryos had a reduced A-P body axis. A similar defect was observed in zebrafish 
embryos, indicating conservation of a role for YAP in completion of gastrulation and axis 
elongation across frog, fish, and mouse. While germ layer inductions occurred in the absence 
of xYAP, the onset of mesodermal gene expression was perturbed, indicating that YAP is 
required during the early steps of mesodermal fate specification. These results demonstrate 
that the previously described A-P axis defect in YAP mutant mice is not simply due to 
nutritional deficiencies.  
  
Increasing YAP expands progenitors and inhibits their differentiation 
 When wild type xyap, myap, or hyap RNAs were injected into Xenopus laevis embryos, 
major morphological defects became apparent at tail bud stages, when tissue progenitors are 
differentiating into functional cell types. Because the tissue perturbations were widespread, 
we predicted that gene expression changes occurred during earlier patterning events. In fact, 
we observed that at neural plate stages two progenitor populations were expanded (sox2+ 
neural plate; pax3+ neural crest), whereas differentiation markers of these tissues as well as of 
somitic muscle and epidermis were repressed. These results are consistent with the report that 
the small intestinal progenitor pool was expanded when YAP was specifically overexpressed 
in the small intestines of mice (Camargo et al., 2007). The mechanism by which the 
expansion of progenitors in frog embryos is accomplished is not yet known. The expansion 
of mouse intestinal progenitors is mediated by activation of the Notch pathway by YAP 
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(Camargo et al., 2007); however, frog embryos injected with xyap mRNA showed reduced 
notch and hes1 RNA expression. Interestingly, xYAP did not expand all progenitors or all 
pax3-expressing cells. YAP gain-of-function inhibited pax3 expression in hatching gland 
precursors, and reduced the expression of six1, a transcription factor that maintains the PPE 
in a progenitor state (Brugmann et al., 2004, Schlosser et al., 2008). These results 
demonstrate that YAP-mediated expansion of progenitor populations has tissue specificity, 
even within the embryonic ectoderm.  
 
xYAP directly regulates pax3 transcription 
The effects of altering YAP levels on pax3 expression in the neural crest progenitors 
suggested that YAP directly regulates pax3 transcription. Increasing evidence suggests that 
the interaction of YAP with the TEAD family of transcription factors is critically important 
for proper vertebrate development (Cao et al., 2008, Nishioka et al., 2009, Sawada et al., 
2005, Yagi et al., 2007). Therefore, we searched for highly conserved TEAD binding sites in 
the 5’ regulatory region of pax3 and found a previously undescribed, TEAD-binding site 
within this region. Increased expression of TEAD1 phenocopied the xYAP-mediated 
expansion of pax3 in the neural crest progenitors and significantly enhanced this phenotype 
following coexpression of xtead1 with levels of xyap mRNA that were ineffective on their 
own. Importantly, we demonstrated the in vivo relevance of this predicted association by 
ChIP analysis. Endogenous YAP localized to this newly identified TEAD-binding site within 
the 5’ regulatory region of pax3, but not to a region of the pax3 promoter lacking putative 
TEAD binding sites. In addition, a region of the sox2 promoter containing a putative TEAD 
binding site also did not co-immunoprecipitate with YAP. We have yet to confirm whether 
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endogenous TEAD1 resides on this region or whether other TEADs are present. For 
example, there is evidence that TEAD1 and TEAD2 can functionally compensate for each 
other in early mouse development (Chen, Z. et al., 1994, Sawada et al., 2008). Nonetheless, 
these experiments demonstrate a new developmental role for both TEAD and YAP in 
cooperatively driving pax3 expression in neural crest progenitors.  
Our structure/function analyses, however, indicate that the expansion of the pax3 
neural crest progenitors likely involves YAP binding to proteins in addition to TEADs, 
because deletion of domains other than the TEAD-binding site also reduced this effect. In 
fact, the different effects of YAP on different ectodermal and mesodermal genes appear to 
require different protein interaction domains, confirming that the ability of YAP to bind to 
multiple proteins endows this protein with diverse functions. Here, we have illuminated a 
few key developmental roles for YAP, which appear to be consistent across three vertebrates. 
Moving forward, it will be interesting to see whether it is YAP’s transcriptional activation 
abilities or its function as a scaffolding protein that is more important for each specific effect. 
An intriguing notion is that YAP may act as a critical scaffolding protein within the nucleus 
to assist in the regulation of transcription or regulate the state and/or remodeling of 
chromatin. 
Chapter III – Transcriptional control of YAP 
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Introduction 
Regulation of gene expression is critically important in development, as it controls 
the growth, survival, mobility, and function of each cell. Improper regulation of gene 
expression can lead to a variety of developmentl defects, such as loss of conceptus, birth 
defects, and cancer (Gavert et al., 2007, Jacob et al., 2007, Semenza, 2000). Determining the 
spatial and temporal expression of genes in different cells provides insight into a gene’s 
involvement in these processes (Andersson et al., 2007, Zurita et al., 2008). Due to the high 
level of conservation in developmental processes across mammals, the mouse is a favored 
model organism for studying the functions of genes whose presence is critical for proper 
embryogenesis. 
From our work, we concluded that Yes-associated protein (YAP) is critical for early 
embryonic development (Morin-Kensicki et al., 2006). YAP is a modular adaptor protein 
with multiple protein interaction domains and can function as both a scaffolding protein and 
a transcriptional co-activator. To determine the in vivo importance of this scaffolding 
complex, we used homologous recombination to remove YAP from the mouse and found that 
few embryos survived past E8.5. YAP expression is also shown to be elevated in cancer 
(Dong et al., 2007, Overholtzer et al., 2006). Studying the transcriptional regulation of YAP 
provides insight into the mechanisms by which it functions. To understand yap at the RNA 
level, it is important to identify and characterize the regulatory elements of the yap promoter. 
 The yap promoter does not contain a canonical TATA or CAAT box, which are 
traditionally known to regulate transcription. Thus, yap is controlled by a TATA-less 
promoter, which is common among maternally expressed and/or housekeeping genes (Figure 
29). To better understand the transcriptional regulation of yap, deletion analysis of the yap
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Figure 29: Comparison between a TATA-containing and a TATA-less promoter. There 
are two types of promoters, TATA-containing promoters and TATA-less promoters. TATA 
boxes are typically located 25-30 bp upstream of the transcriptional start site and direct 
transcription by interacting with a transcription factor known as TATA-binding protein 
(TBP) (Parker et al., 1984). TBP is one component of a larger complex known as 
transcription factor IID (TFIID). When TFIID binds to a TATA box, it initializes the 
formation of a larger pre-initiation complex, which contains RNA polymerase II (Buratowski 
et al., 1989). RNA polymerase II is responsible for the transcription of almost every gene. 
Sometimes, a CAAT box accompanies the TATA box to enhance binding of the 
transcriptional machinery for transcriptional initiation; however, CAAT boxes are not always 
necessary for transcriptional initiation. TATA-less promoters contain a control element 
known as an initiator (Inr) (Smale et al., 1989). An Inr is considered a functional analog of 
the TATA box, and is sufficient alone for directing the initiation of transcription (Chen, W. et 
al., 1985, Smale et al., 1989). Another type of TATA-less promoter is one that contains CpG 
islands. 
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promoter was performed based around repetitive regions of the genomic DNA. Promoter 
activity for the various deletion constructs of the yap promoter was tested by directionally 
cloning the construct into a luciferase reporter vector and transfecting them into established 
fibroblast and epithelial cell lines. Based on these data, our analysis was narrowed to a 
specific, conserved region of the yap promoter. This conserved region was further studied to 
identify sites controlling promoter activity, and specific sites were characterized to identify a 
transcription factor regulating yap expression at the RNA level. 
 
Methods and Materials 
Cloning of yap Promoter Constructs into a Luciferase Reporter Vector 
 Primers were designed to include MluI and XhoI sites such that the resulting PCR-
amplified fragment could be easily cloned into the multicloning site of the pGL3-basic vector 
(Promega). Various 5’ upstream fragments, (-2828/+28), (-1819/+28), (-1374/+28), (-
500/+28), and (-141/+28), of yap were amplified by PCR and inserted in front of the 
luciferase reporter gene in the pGL3-basic expression vector. The numbering of the 
fragments was based on the currently accepted transcriptional start site. The fragments were 
ligated into the pGL3-basic vector at the MluI and XhoI sites. To construct a mutant promoter 
fragment, primers containing a point mutation in the putative Sp1 binding site were 
constructed. The primers were used with the QuikChange® Site-Directed Mutagenesis Kit 
(Stratagene) to amplify a mutated yap promoter fragment (-141/+28). The yap promoter 
region and the inserts were sequenced to confirm proper amplification and ligation into the 
reporter vector (UNC-CH Genome Analysis Facility). 
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Cell Culture 
 NIH-3T3 cells, a mouse fibroblast cell line, and M1 cells, a mouse epithelial cell line 
derived from a microdissected cortical collecting duct of a mouse transgenic for the early 
region of simian virus 40 (SV40), Tg(SV40E)Bri/7, were grown on 100 mm plates in 
Dulbecco’s Complete Growth Serum with 10% fetal bovine serum (FBS) and 
penicillin/streptomycin antibiotics (Stoos et al., 1991). 
 
Transfection and Luciferase Assay 
 Cells were grown to approximately 90-95% confluence on a 16 mm-diameter plate 
and transfected with Lipofectamine 2000 (Invitrogen) using 0.4 µg of plasmid DNA 
containing the yap promoter fragment. To normalize for transfection efficiency, 0.4 µg of 
plasmid vector containing the lacZ gene was cotransfected. The lacZ gene was under the 
control of the actin promoter. The transfected cells were lysed in 110 µL of Glo Lysis Buffer 
(Promega). The luciferase assay was performed according to the protocol for the luciferase 
assay system (Promega), and the relative activity was measured with a luminometer 
(Berthold Detection Systems). 
 For the β-galactosidase (β-gal) assay, 30 µL of cell lysate was added to 201 µL of 
sodium phosphate buffer (0.1 M, pH 7.5), 3 µL of 100x Mg2+ solution (0.1 M MgCl2, 4.5 M 
β-mercaptoethanol), and 66 µL of 1x ONPG (Sigma) in sodium phosphate buffer (Sambrook 
et al., 2001). The reaction was carried out in a 37oC incubator for at least 30 minutes and 
stopped by adding 500 µL of 1 M sodium carbonate. β-gal activity was determined by 
measuring the level of the hydrolysis product of ONPG at a wavelength of 420 nm (µQuant, 
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Bio-Tek Instruments, Inc.). The luciferase activity was normalized according to the β-gal 
activity by taking the ratio of luciferase activity to β-gal expression in the cells. 
 
Preparation of Nuclear Extracts 
 Nuclear extracts were prepared from NIH-3T3 and M1 cells according to established 
methods (Sambrook et al., 2001). Briefly, the cells were collected by centrifugation at 250 x 
g for 10 minutes at room temperature and rinsed with phosphate-buffered saline several 
times. The cells were then resuspended in ice-cold cell homogenization buffer (10 mM 
HEPES-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 M dithiothreitol, 0.5 mM 
phenylmethylsulfonyl fluoride), incubated on ice for 10 minutes, and then collected again by 
centrifugation. The cell pellet was resuspended in ice-cold cell homogenization buffer 
containing 0.05% Nonidet P-40 and the cells were homogenized in ice with 20 strokes of a 
tight-fitting Dounce homogenizer. The nuclei were then collected by centrifugation at 250 x 
g for 10 minutes at 4°C. The nuclei pellet was resuspended in 1 mL of ice-cold cell 
resuspension buffer (40 mM HEPES-KOH pH 7.9, 0.4 M KCl, 1 mM dithiothreitol, 10% 
(v/v) glycerol, 0.1 mM phenylmethylsulfonyl fluoride, 1x Complete-EDTA protease 
inhibitor), 5 M NaCl was added to a final concentration of 300 mM, and the suspension was 
incubated on ice for 30 minutes. The nuclear extract was then recovered by centrifugation at 
104,000 x g for 20 minutes at 4oC and stored at -80oC. Protein concentrations were 
determined using the Bradford method (Bio-Rad Laboratories). 
 
Electrophoretic mobility shift assay (EMSA) 
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The oligonucleotides myap f 5’-CGA GGC GCG CGG GCG GGC GCT CCT CGC 
AAC-3’ and myap r 5’-GTT GCG AGG AGC GCC CGC CCG CGC GCC TCG-3’ were 
synthesized (LI-COR) and annealed to generate a double-stranded myap promoter fragment 
corresponding to the region in (-141/+28) containing the putative Sp1 binding site. A 2% 
agarose gel was run to confirm that the oligonucleotide was double-stranded. An 
oligonucleotide containing the consensus Sp1 binding sequence was obtained for use as a 
positive control (LI-COR). The oligonucleotides were end labeled with an infrared dye that 
fluoresces at 700 nm (LI-COR). The binding reaction was performed according to a 
standardized protocol (LI-COR) using 1.5 µg of NIH-3T3 and M1 nuclear lysates. A 4% 
nondenaturing polyacrylamide gel was prepared and the products of each binding reaction 
were run at 10 V/cm in 1X TBE (89 mM tris, 89 mM boric acid, 2 mM Na4EDTA, pH 8.3) 
for 180 minutes and the gel was imaged using the Odyssey Imaging System (LI-COR). A 
supershift of the binding was performed by incubating the binding reaction for an additional 
30 minutes at room temperature in the presence of a Sp1 antibody (Santa Cruz 
Biotechnologies, Inc.). A competition assay was performed, in which the binding reaction 
was incubated with an unlabeled double-stranded myap promoter oligonucleotide at a 
concentration of 50x and 100x. 
 
Results 
Deletion construct (-141/+28) maintained yap promoter activity 
 An online database, RepeatMasker, was utilized to design primers around the 
repetitive sequences of genomic DNA, which contained the yap promoter. Primers were 
obtained to amplify the constructs (-2828/+28), (-1819/+28), (-1374/+28), and (-500/+28) of 
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the yap promoter. The different deletion constructs were directionally cloned into the 
multiple cloning site of a pGL3-basic reporter vector using the restriction enzymes XhoI and 
MluI. Each clone of the deletion construct was sequenced to ensure proper insertion. The 
pGL3-basic vector contains the luciferase gene, whose transcription is initiated by activators 
in the deletion constructs. The empty pGL3-basic vector provided a baseline for promoter 
activity. The highest level of promoter activity initially observed was in the (-500/+28) 
deletion construct (data not shown).  
 According to the UCSC Genome Browser, the fragment of greatest interest in this 
experiment was the (-141/+28) deletion construct because it was highly conserved across 
species, such as mouse, rat, dog, and human (Figure 30). In NIH-3T3 cells, the deletion 
construct (-141/+28) maintained a 15-fold increase in luciferase activity relative to the 
baseline (Figure 31). Similarly, in M1 cells, the highest relative activity was observed in (-
141/+28) (Figure 32). 
 
Mutation of a putative Sp1 binding site in (-141/+28) reduced YAP promoter activity 
An online database, Proscan, identified multiple putative Sp1 binding sites within a 
region of the (-141/+28) deletion construct. A putative Sp1 binding site 34 bp upstream of 
the transcriptional start site was chosen for study based on the match attained in Proscan, and 
two adjacent nucleotides were mutated (Table 2).  
After confirming proper mutation of the putative Sp1 binding site by sequencing, 
promoter activity in NIH-3T3 and M1 cells was analyzed by performing the luciferase and β-
gal assays. The deletion construct of (-141/+28) with the first mutated putative Sp1 binding
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Figure 30: Alignment of myap proximal promoter region. Alignment of proximal 
promoter region 150 bp upstream of yap transcriptional start site in different species. 
Conservation across species is shown in the solid blue peaks. 
 117 
 
 
 
 
 118 
Figure 31: Relative myap promoter activity in NIH-3T3 fibroblasts. Relative yap 
promoter activity over the baseline vector. The activities were normalized by taking the ratio 
of luciferase activity to β-gal activity in NIH-3T3 cells. Error bars represent standard error  
(n = 12). 
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Figure 32: Relative myap promoter activity in M1 epithelial cells. Relative yap promoter 
activity over the baseline vector. The activities were normalized by taking the ratio of 
luciferase activity to β-gal activity in M1 cells. Error bars represent standard error (n = 12). 
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Table 2. Comparison of the sequence of wild type to first mutated yap (-141/+28) 
fragment. The region highlighted in blue represents the putative Sp1 binding site based on a 
consensus sequence for the antibody produced by Santa Cruz Biotechnologies, Inc (5’-GGG 
GCG GGG C-3’). 
 
 Sequence 
yap (-141/+28) 5’ – CGC GGG CGG GCG CGC GGA GCG - 3’ 
yap Sp1 mutant 1 (-141/+28) 5’ – CGC GGG CTT GCG CGC GGA GCG - 3’ 
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site had a significantly lower amount of yap promoter activity in NIH3T3 (Figure 33, P < 
0.0001, n = 12) and M1 (Figure 34, P < 0.0003, n = 9) cells. 
Another putative Sp1 binding site was analyzed in order to identify what was 
controlling the remaining promoter activity. Two adjacent base pairs in a second site 48 bp 
upstream of the transcriptional start site were mutated (Table 3). The Sp1 mutant 2 of (-
141/+28) did not significantly reduce promoter activity in NIH-3T3 (Figure 33) or M1 
(Figure 34) cells. These results indicate that while the first Sp1 site is important for YAP 
transcription in both fibroblasts and epithelial cells, it is not solely responsible for YAP 
transcription, suggesting that other proteins may be involved in forming a transcriptional 
complex for recruiting the RNA polymerase II transcriptional machinery.    
 
Sp1 is responsible for shifing a yap promoter oligonucleotide 
 
An EMSA (Electrophoretic Mobility Shift Assay) was performed to show that Sp1 
specifically binds to the promoter at the first putative Sp1-binding site. When nuclear 
extracts, from NIH-3T3 and M1 cells, are incubated in the presence of oligonucleotides, they 
bind to the DNA to form a protein-DNA complex. When labeled oligonucleotides are 
separated by electrophoresis, any proteins binding to these oligonucleotides will reduce the 
mobility of these IRdye-labeled oligonucleotides.  
A 30-bp forward and reverse oligonucleotide was designed to contain the first 
putative Sp1-binding site that resulted in reduced promoter activity in both NIH-3T3 and M1 
cells. Single-stranded and double-stranded oligonucleotides were electrophoresed on an 
agarose gel and imaged at 700 nm with an Odyssey Imaging System to confirm annealing of 
the IRdye labeled olignucleotides (Figure 35). Using these oligonucleotides, binding 
 124 
Figure 33: Mutation of Sp1 site reduced myap promoter activity in fibroblasts. 
Percentage of promoter activity relative to the normal (-141/+28) deletion construct in NIH-
3T3 cells. Sp1 Mutant 1 represents the construct with two adjacent nucleotides mutated 36 bp 
upstream of the transcriptional start site. Sp1 Mutant 2 represents the construct with two 
adjacent nucleotides mutated 48 bp upstream of the transcriptional start site. Promoter 
activity was significantly reduced in the presence of Sp1 Mutant 1 (P < 0.0001, n = 12). Sp1 
Mutant 2 had no effect on promoter activity. 
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Table 3. Comparison of the sequence of wild type to second mutated yap (-141/+28) 
fragment. The region highlighted in blue represents the putative Sp1 binding site based on a 
consensus sequence for the antibody produced by Santa Cruz Biotechnologies, Inc (5’-GGG 
GCG GGG C-3’). 
 
 Sequence 
yap (-141/+28) 5’ – GCG GAG CCC GCG AGG - 3’ 
yap Sp1 mutant 2 (-141/+28) 5’ – GCG GAG CTT GCG AGG - 3’ 
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Figure 34: Mutation of one putative Sp1 site reduced myap promoter activity in 
epithelial cells. Percentage of promoter activity relative to the normal (-141/+28) deletion 
construct in M1 cells. Sp1 Mutant 1 represents the construct with two adjacent nucleotides 
mutated 36 bp upstream of the transcriptional start site. Sp1 Mutant 2 represents the construct 
with two adjacent nucleotides mutated 48 bp upstream of the transcriptional start site. 
Promoter activity was significantly reduced in the presence of Sp1 Mutant 1 (P < 0.0003, n = 
9). Sp1 Mutant 2 did not reduce promoter activity. 
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reactions with nuclear extracts from NIH-3T3 and M1 cells were performed and run out on a 
4% nondenaturing polyacrylamide gel. Based on the results of the EMSA assay, a complex 
containing the yap promoter oligonucleotide and bound transcription factors co-migrated 
with the positive control oligonucleotide containing a consensus Sp1-binding site (Figure 36, 
upper band), while several nonspecific, lower bands also migrated in the presence of the 
oligonucleotides. To determine the reason for the nonspecific binding, nuclear extracts were 
incubated individually with the forward and reverse oligonucleotides (Figure 37). Results 
from this experiment illustrated that these nonspecific bands are due to the binding of 
residual single-stranded oligonucleotides. The specific Sp1 shift was present and consistent 
in both cell types. A competition assay was performed using unlabeled yap promoter 
oligonucleotide at concentrations of 50 and 100 times that of the labeled yap promoter 
oligonucleotide. When the unlabeled yap promoter oligonucleotide was added to the labeled 
consensus Sp1 oligonucleotide, the intensity of the shifted band was reduced. The same 
reduction was seen when the unlabeled yap promoter oligonucleotide was added to the 
labeled yap promoter oligonucleotide (Figure 36). There was greater reduction in the 
intensity of the shifted band with 100x excess compared to 50x excess unlabeled yap 
promoter oligonucleotide. These combined results suggest that the electromobility shift of the 
labeled oligonucleotides is due to Sp1.  
To further confirm that the transcription factor binding to the yap promoter 
oligonucleotide was Sp1, the binding reaction was incubated with an Sp1 antibody. 
Normally, the antibody will bind to the protein-DNA complex, leading to what is called a 
supershift, whereby the mobility is further reduced. However, no supershift was observed 
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Figure 35: Annealing of myap promoter oligos for gel-shift analysis. Annealing of the two 
oligos (mYAPf and mYAPr) containing the putative Sp1 binding site within the myap 
promoter fragment was confirmed by gel electroporesis. Both single-stranded oligos, mYAPf 
and mYAPr, at two different quantities (1 µl and 2 µl) migrated faster than that of the slower, 
double-stranded oligo (annealed lane). 
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Figure 36: Competitive gel-shift assay for Sp1 site in the mYAP promoter. Gel shift 
assay shows competition between labeled and unlabeled YAP oligos for Sp1 binding. Lane A 
shows the IRdye labeled double-stranded YAP oligo. Lane B shows the inhibited migration 
of a positive control IRdye labeled Sp1-binding site containing double-stranded oligo in the 
presence of nuclear extracts from NIH-3T3 or M1 cells. Lane C shows that 50x excess of the 
unlabeled YAP oligo competes for Sp1 binding to the positive control, Sp1 oligo. Lane D 
shows the inhibited migration of the YAP oligo in the presence of nuclear extracts from NIH-
3T3 and M1 cells, containing Sp1 (top band) as well as unknown or nonspecific (NS, lower 
bands) proteins. Comparing this lane with the positive control (Lane B) suggests that Sp1 can 
bind to the YAP oligo. Lanes E and F show both 50x and 100x unlabeled YAP oligo, 
respectively, competes for Sp1 binding to the YAP oligo. 
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with the addition of Sp1 antibody with either the consensus Sp1 or yap promoter 
oligonucleotides (Figure 37). Instead, the intensity of the band was reduced, suggesting that 
the Sp1 antibody competes for Sp1 with the DNA. Other studies have shown similar results 
using Sp1 antibody in a gel supershift assay (Dean et al., 2000). 
 
Discussion 
To identify and characterize the elements of the yap promoter, an analysis of the 
promoter was performed to narrow the focus of study to a small region containing potential 
regulatory elements. Different deletion constructs of the yap promoter up to 3 kbp upstream 
of the transcriptional start site were designed using RepeatMasker, an online database that 
searches for repeated sequences in genomic DNA. When the luciferase reporter vector 
containing each deletion construct was transfected into cells, the transcriptional machinery 
bound to the reporter construct and initiated transcription of the luciferase gene. A luciferase 
substrate was utilized to determine the promoter activity of each deletion construct. Analysis 
of the promoter was narrowed to 500 bp upstream of the transcriptional start site for myap 
after it maintained the highest levels of promoter activity. A search on the UCSC Genome 
Browser indicated that the region 150 bp upstream of the transcriptional start site was highly 
conserved across species; thus it was hypothesized that this region was sufficient for high 
levels of yap promoter activity.  
In both NIH3T3 and M1 cells, the deletion construct (-141/+28) maintained the 
highest level of promoter activity, while the larger constructs had much lower levels of 
activity. These lower levels of activity could be due to the presence of repressors or other
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Figure 37: Competitive gel-shift assay and supershift of Sp1. Lane A shows the IRdye 
labeled double-stranded YAP oligo. Lane B shows the inhibited migration of a positive 
control IRdye labeled, Sp1-binding site containing, double-stranded oligo in the presence of 
nuclear extracts from NIH-3T3 or M1 cells. Lane C shows that addition of a Sp1 antibody 
competes for Sp1 binding to the Sp1 oligo. Lanes D and E illustrate that the nonspecific 
bands (NS) that inhibit the YAP oligo migration are due to proteins binding to the single-
stranded, unannealed oligos (YAP reverse oligo and YAP forward oligo). Lane F shows the 
inhibited migration of the YAP oligo in the presence of nuclear extracts from NIH-3T3 and 
M1 cells, containing the Sp1 (top band) protein as well as the nonspecific (NS, lower bands) 
proteins. Comparing this lane with the positive control (Lane B) suggests that Sp1 can bind 
to this oligo. Lane G shows that addition of a Sp1 antibody competed for Sp1 (top band) 
binding to the YAP oligo as it did in the presence of the positive control Sp1 oligo. 
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processes of regulation, such as epigenetic marks. After demonstrating that the (-141/+28) 
construct maintained the highest level of promoter activity, the next step was to identify 
potential activators within the region of the (-141/+28) construct. According to an online 
database, Proscan, the region up to 150 bp upstream of the transcriptional start site contains 
several putative Sp1 binding sites. Sp1 is a transcription factor that binds to GC boxes. The 
yap promoter is rich in guanine and cytosine, nucleotides of which GC boxes are composed. 
Sp1 is associated with TATA-less promoters that contain regions rich in guanine and 
cytosine, and can recruit the components of the transcriptional machinery, such as RNA 
polymerase II, to the promoter (Smale, 1994). In addition, Sp1, like YAP, is ubiquitously 
expressed in most cells during development. Sp1 is present in the early stages of embryonic 
development, and is known to regulate transcription of other genes during embryogenesis 
(Smale, 1994). Promoters whose transcription is regulated by Sp1 usually contain multiple 
Sp1 binding sites, each having slightly different DNA sequences and thus different binding 
affinities for Sp1 (Dynan et al., 1983, Gidoni et al., 1985). The possibility for Sp1 regulating 
yap transcription is further supported by evidence that mice lacking Sp1 are always smaller 
than their littermates and exhibit a range of defects including defective body axis symmetry, 
incomplete turning, and growth outside the yolk sac; however, these mice were stated to 
survive to E10-11 (Marin et al., 1997). The extended life span of the Sp1-null mice compared 
with the YAP-null mice could be due to compensation from another protein, such as Sp3. 
Interestingly, the differentiative capacity of Sp1-/- cells does not appear to be severely 
impeded, since many of the structural hallmarks of normal E8.5–9.5 embryos in the best-
developed Sp1-/- embryos remain. 
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 Based on the results obtained, Sp1 Mutant 1, which was a mutation in a putative site 
36 bp upstream of the start site, significantly reduced promoter activity in both NIH-3T3 and 
M1 cells. These data suggest that the site located in Sp1 Mutant 1 is essential for activating 
promoter activity. Sp1 Mutant 2, which was a mutation in the potential site 48 bp upstream of 
the start site, had no effect on promoter activity in NIH-3T3 cells, but actually increased 
promoter activity in M1 cells. It is likely that the two adjacent point mutations made in Sp1 
Mutant 2 created an activation site for another transcription factor unique to M1 cells, 
leading to an increase in promoter activity. The activity reduced by Sp1 Mutant 1 in NIH-
3T3 and M1 cells was only 40 to 60 percent, respectively, so there must be another site in the 
region controlling the remaining promoter activity. This coincides with previous studies 
indicating that there are usually multiple Sp1 binding sites regulating transcription (Dynan et 
al., 1983, Gidoni et al., 1985). 
Although these results are highly suggestive that Sp1 plays a critical role in YAP 
expression, they are not yet definitive. To further characterize the role of Sp1 in controlling 
yap transcription, YAP expression could be analyzed when Sp1 is overexpressed or knocked 
out of cells. In the future, other regulatory elements that regulate yap transcription are likely 
to be identified. Based on an online database, UCSC Genome Browser, the first intron of yap 
is also highly conserved, and thus, could possibly serve as a site of transcriptional regulation. 
Further studies of yap expression and regulation will be beneficial in determining 
YAP’s role in development. For example, different elements of the yap promoter could be 
used to drive the expression of Green Fluorescence Protein (GFP) or LacZ to determine what 
regions of the promoter are sufficient to mediate yap expression in localized regions of the 
mouse, zebrafish, or frog embryos. Identification of these elements can then be used to 
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determine whether transgenic expression of YAP is sufficient to rescue defects observed in 
YAP-deficient mice, zebrafish, or frog. The ability to rescue the developmental defects 
associated with YAP-deficient mice, zebrafish, or frog would demonstrate specificity in 
YAP’s diverse roles during development. 
Chapter IV – Identification of putative YAP transcriptional target genes 
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Introduction 
 Although we knocked out the transcriptional co-activator, YAP, in mouse, frog, and 
zebrafish and confirmed the presence of YAP on the pax3 promoter in vivo, the number of 
known gene targets associated with YAP mediated transcription remains limited. Given that 
we possessed a mouse lacking the YAP gene, I created an immortalized cell line of mouse 
embryonic fibroblasts (MEFs) isolated from the YAP mutant mice. The rationale for creating 
these cells was that gene targets should be easily identified by comparing gene expression 
profiles between wild type and YAP mutant immortalized cell lines. Similar efforts have 
been succussful, for example the Src, Yes, Fyn (SYF) triple mutant MEF cell lines were 
created from similarly aged mutant embryos as YAP mutant embryos (Klinghoffer et al., 
1999). With assistance from Elizabeth Morin-Kensicki and Jim Bear, immortalized MEF cell 
lines were created from our YAP mutant mice, and in so doing, at least one potential new 
YAP gene target was identified. 
 
Methods and Materials 
Isolation and immortalization of mouse embryonic fibroblasts (MEFs) 
 Embryonic day 8.5 (E8.5) mice were isolated from pregnant CD57BL/6J females 
heterozygous for the targeted Yaptm1Smil allele (Morin-Kensicki et al., 2006), dissected in 1X 
PBS, exposed to trypsin for 10 min at 37°C, physically dissociated by pipetting up and down, 
and each embryo was plated in a single well of 24-well fibronectin coated tissue culture 
plate. Subsequently, the cells were passaged to normal tissue culture plates and maintained in 
DMEM-High glucose and 10% FBS at 37°C.  
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At passage two, cells were exposed to SV40 large T antigen retrovirus conditioned 
media from Ψ2 packaging cells and supplemented with polybrene (4 µg/mL) at 32°C 
overnight (Brown et al., 1986). A well of cells isolated from each wild type or heterozygous 
embryo was not exposed to the retroviral-conditioned media and served as a control for 
determining immortalization of the cell lines. The retroviral and MEF conditioned media was 
removed and inactivated with bleach. The control cells hit their crisis point by passage 8, 
while the cells exposed to the SV40 Large T antigen retrovirus continued to multiply and 
were considered to be immortalized by passage 10. To properly genotype the isolated cell 
lines, genomic DNA was isolated from each immortalized cell line and PCR was performed 
as previously described (Morin-Kensicki et al., 2006). 
 
Western blot 
 Cells from each immortalized MEF cell lines were lysed in RIPA buffer and the 
insoluble fraction was pelleted at 13,000 x g for 5 min at 4°C. Total protein concentrations 
were quantified using the BCA Protein Assay Kit (Pierce), according to the manufacturer’s 
protocol. Equal amounts of protein were loaded onto a 10% SDS-PAGE gel, separated by 
electrophoresis, transferred to a PVDF membrane, blocked in Odyssey Blocking Buffer (Li-
Cor) for 1 hour at room temperature, and co-probed for mYAP using an affinity purified 
rabbit anti-YAP antibody (1:1000), which was generated against human YAP (274-454) 
(Howell et al., 2004) and a mouse anti-Actin antibody (Clontech), for 1 hr at room 
temperature. The blots were washed three times with TBST at room temperature and exposed 
to anti-rabbit IRDye 800 (1:20,000) and anti-mouse IRDye 680 (1:20,000) secondary 
antibodies for 1 hour at room temperature. The blots were washed three times with TBST and 
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once with 1X PBS to remove the Tween 20 (Sigma). The blots were then scanned on a Li- 
Core Odyssey. 
 
Removal of mutant mYAP from YAP-/- MEFs 
Turbo-Cre was removed by restriction digestion with EcoRI and subcloned into the 
bicistronic mammalian retroviral expression vector, pMIG-RI. Because subcloning with one 
restriction enzyme may result in concatemers, restriction digests with SalI and XhoI 
confirmed the identity of a single copy. Similarly, proper gene orientation within the vector 
was confirmed by restriction digest with NcoI.  
Phoenix cells, a retroviral packaging cell line, were maintained in DMEM-high 
glucose and 10% FBS. Transfection of the pMIG-RI and pMIG-RI-Turbo-Cre recombinase 
into the packaging line was performed using lipofectamine (Invitrogen), according to 
manufacturer’s protocol. After three days, the conditioned media from the transfected 
packaging cell line was removed and filtered through a 0.45 micron filter and stored at 4°C. 
Media from mutant YAP MEFs plated at sixty percent confluence was removed and replaced 
with warm (32°C) retroviral conditioned media (pMIG-RI or pMIG-RI-Turbo-Cre-
recombinase) supplemented with 4 µg/ml polybrene. After four hours, the retroviral-
conditioned media was removed, inactivated with bleach, and replaced with DMEM-high 
glucose and 10% FBS. After two days, the retroviral infected mutant YAP MEFs were split 
and further propagated. To confirm viral integration of the pMIG-RI and pMIG-RI-Turbo-
Cre recombinase vectors into the mutant YAP MEFs genome, cells were trypsinized, washed 
with 1X PBS, well resuspended in 1X PBS with 1% FBS plus P/S, filtered to single cell 
suspension (5 x 106 cells/mL), and cell sorted by the NHGRI cell sorting core facility. Only 
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1% of the each of the sorted cells was GFP positive, but they were plated into two 12-well 
sized wells. These cells were expanded and sorted for GFP positive cells three more times in 
attempts to retrieve as pure of a cell population as possible that lacked the mutant mYAP.  
 
Microarray 
 High quality RNA was isolated from a wild type MEF cell line and a YAP-/- cell line 
using the RNeasy Plus Qiagen kit, according to the manufacturer’s protocol. The RNA was 
treated with DNase (Promega) according to the manufacturer’s specifications and quantified 
using a Nanodrop. The isolated RNA was considered to be of high quality if the A260/A280 
ratio was above 1.8. The RNA was given to the NHLBI Microarray facility, which amplified 
the product by reverse transcribing the RNA into cDNAs and probed full genome mouse 
microarrays with the resulting cDNAs. The NHLBI MicroArray facility then provided a list 
of genes that showed greater than two fold changes in either direction.  
 
RT-PCR 
 Total RNA was isolated from MEF cell lines (two wild type YAP MEF lines and one 
YAP-/- MEF line) as described above, and 1 µg of RNA was reverse transcribed using 
random hexamer priming and Superscript II reverse transcriptase (Invitrogen), according to 
the manufacturer’s specifications, while a control for each sample was exposed to all 
reagents except the reverse transcriptase. For PCR analyses, 1 µl of the resulting RT products 
were used in 25 µl reactions. Gene specific primers for adrenomedullin (Forward: GAG 
CGA AGC CCA CAT TCG T, Reverse: GAA GCG GCA TCC ATT GCT), rasgap3 
(Forward: GTG GAG CCA ATT GTC ACA AAC AGT G, Reverse: GCC TGT AAC CAG 
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TGT GAT GGC TCT G), follistain-like 3 (Forward: GTT CCT GGG CCT CGT CCA C, 
Reverse: CGG TAC ATG ACG CGC AAG), arhgap22 (Forward: TCC TAA CAT TCT 
TCG GCC AC, Reverse: CTG GTG ACC TCT TCA GAG CC), edg7 (Forward: GAA TTG 
CCT CTG CAA CAT CTC, Reverse: GAG TAG ATG ATG GGG TTC A), ephA1 (Forward: 
GCC TGG CCC TTT CTC CCC TG, Reverse: TCT CTG TCT CTG GCC TCT CC), and 
actin (Forward: GCT CCG GCA TGT GCA A, Reverse: AGG ATC TTC ATG AGG TAG 
T) were used to amplify the gene specific products using REDTaq DNA polymerase Ready 
Mix (Sigma) and the following PCR program: ((95°C for 5 min, 25 cycles of: (95°C for 30 
sec, 57°C for 30 sec, 72°C for 45 sec), 72°C for 10 min, and overnight at 4°C)), except for 
the actin primers, which followed this PCR program: ((95°C for 5 min, 18 cycles of: (95°C 
for 30 sec, 55°C for 30 sec, 72°C for 45 sec), 72°C for 10 min, and overnight at 4°C)). The 
PCR products were then resolved on 2% agarose gels and viewed and photographed under 
UV illumination.  
 
Addition of mYAP back to YAP-/- MEF-Turbo-Cre cells 
 YAP-/- MEF-Turbo-Cre cells that were sorted four times and passaged 36 times were 
trypsinized and counted. Two million cells were placed in 50 mL conical tubes, pelleted by 
slow centrifugation (700 rpm) for ten minutes, and resuspended in 100 µl of a room 
temperature mixture of the MEF1 stock solution (Lonza) and the included supplement. After 
resuspension, 5 µg of pCMV-HA-mYAP endotoxin-free maxi prepped (Qiagen) plasmid 
DNA was added to the cell/MEF1 solution. This cell resuspension was then transferred to a 
cuvette and electroporated in an Amaxa electroporator with program T-20. After 
electroporation, 500 µl of warm culture media (DMEM-high glucose with 10% FBS and P/S) 
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was added to the cells and transferred to T-75 tissue culture plates containing 8 mL of warm 
culture media, then placed back into the 37°C incubator.  
 
Cell Culture 
 Jurkat (Clone E6-1) cells are human T cells that were originally isolated from the 
peripheral blood of a 14-year old male with acute T cell leukemia. They are maintained in 
RPMI-1640 culture media supplemented with 10% FBS at a cell concentration of 1 x 105 and 
1 x 106 cells/mL.  
 In order to transfect Jurkat cells with pCMV-HA-mYAP endotoxin-free maxi prepped 
DNA (Qiagen), the cells were electroporated with an Amaxa electorporator. 12-well plates 
with 1 mL of prewarmed growth media were prepared and 1 x 106 cells were pelleted at 90 x 
g for 10 min. The cell pellet was then suspended in 100 µl prewarmed NF solution V 
precombined with the Amaxa supplement with 2 µg of pCMV-HA-mYAP endotoxin-free 
maxi prepped DNA (Qiagen). The cell/DNA suspension was transferred to a cuvette and 
electroporated with program X-05. The transfected cells were then added to one 12-well 
containing the prewarmed growth media. After 24 hours, total RNA was isolated from the 
transfected Jurkat cells with the RNeasy Plus kit (Qiagen). Quantity and quality of the RNA 
was determined using a Nanodrop and was treated with DNase (Promega) according to the 
manufacturer’s protocol. 1 µg of RNA was reverse transcribed using random hexamer 
priming and Superscript II reverse transcriptase (Invitrogen), according to the manufacturer’s 
specifications, while a control for each sample was exposed to all reagents except the reverse 
transcriptase. For PCR analyses, 1 µl of the resulting RT products was used in 25 µl 
reactions. Gene specific primers for human adrenomedullin (Forward: CTG GGT TCG CTC 
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GCC TTC CTA, Reverse: GTT GTC CTT GTC CTT ATC TGT), human actin (Forward: 
GCT CCG GCA TGT GCA A, Reverse: AGG ATC TTC ATG AGG TAG T), and mouse 
yap (Forward: GGG AGC TCT GAC TCC ACA GCA TGT TCG, Reverse: GGC AGA ATT 
CAT CAG CGT CTG GGG C) were used to amplify the gene specific products using 
REDTaq DNA polymerase Ready Mix (Sigma) and the following PCR program: ((95°C for 
5 min, 27 cycles of: (95°C for 30 sec, 55°C for 30 sec, 72°C for 45 sec), 72°C for 10 min, 
and overnight at 4°C)), except for the actin and myap primers, which followed the same 
program except with 20 cycles. The PCR products were resolved on 2% agarose gels then 
viewed and photographed under UV illumination. 
 
Cloning of mouse and human adrenomedullin promoters 
 Genomic DNA was isolated from NIH-3T3 (mouse) and Jurkat (human) cells 
according to established methods. Mouse and human adrenomedullin (adm) promoter 
regions were amplified from the isolated genomic DNA with specific primers containing 
restriction enzyme sites for the subsequent cloning of the madm promotor (Forward: CCG 
CTC GAG GCG AGG AGG CAA CGA GGT CCA GCC, Reverse: CCC AAG CTT GCA 
AAA CCC CAA AGT CCA AG) and hadm promoter (Forward: CGG GGT ACC GCG AGG 
TGG CAG CGA GGT ACA GTC, Reverse: TCC CCC GGG GCA AAA CTC CGA AGT 
CCA AG) into the pGL3-basic luciferase vector (Promega). The resulting PCR products 
were electrophoresed on a 0.8% agarose gel and gel-purified using the QIAquick Gel 
Extraction Kit (Qiagen). The gel-purified products and the pGL3-basic luciferase vector 
(Promega) were then restriction digested with XhoI and HindIII for the madm promoter and 
KpnI and SmaI for the hADM promoter and subcloned using T4 DNA ligase (NEB) and 
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transformed into competent cells (Invitrogen). Positive clones were sent for sequencing and 
confirmed correct based on alignments with the NCBI deposited genomic sequences. 
 
Results and Discussion 
Creation of immortalized MEF cell lines 
To properly genotype the isolated cell lines, genomic DNA was isolated from each 
immortalized cell line and PCR was performed as previously described (Morin-Kensicki et 
al., 2006). PCR analysis confirmed that two wild type, one heterozygous, and one targeted 
Yaptm1Smil allele MEF-SV40 large T antigen cell lines were obtained (Figure 38A). These cell 
lines were continuously passaged and stored in liquid nitrogen. 
 
Identification and correction of error with the targeted YAPtm1 allele 
After confirming the genotypes of the MEF cell lines, to be comprehensive in our 
analysis, a western blot to illustrate the lack of mYAP within our isolated MEF cell lines was 
performed. Indeed, a band corresponding to the full length YAP was missing from the YAP-
null targeted cell line, but an equally strong band slightly lower than the wild type band for 
YAP was present in both the heterozygous and homozygous YAP targeted cell lines (Figure 
38B,C).  Given that the neomycin resistence gene within the targeted gene allele was not 
removed from the ES cells before they were put into pseudopregnant female mice, we were 
concerned that the promoter of the neomycin resistant gene was not sufficiently stalled and 
allowed continued in-frame transcription of the yap gene. Elizabeth Morin-Kensicki 
performed a series of RACE experiments to determine exactly what yap transcript was 
produced at the targeted Yaptm1Smil allele. The resulting mutant YAP protein was missing the
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Figure 38: PCR and western blot analyses identify the genotype of the MEF 
immortalized cell lines. A) PCR analysis of isolated genomic DNA from the respective 
MEF cell lines show the identity of two wild type immortilized MEF cell lines (+/+ A, B), a 
heterozygous line (+/-), and a homozygous targeted YAP allele line (-/-). B) Western blot 
analysis using our polyclonal YAP antibody (green bands) revealed that our YAP targeted 
mouse was not a true null as evidenced by the lower YAP bands in the null MEF cell lines. A 
monoclonal antibody aganst Actin (red bands) was used as a loading control.  Note: mYAP 
was added back to the YAP null/mutant cell line using a retrovirus (-/- w/ YAP virus). C) 
Western blot analysis of the MEF cell lines after stabling expressing Cre recombinase (-/- 
MEF + Cre virus) via retroviral infection showed that removal of the neomycin resistant gene 
prevented the mutant YAP transcript from being transcribed and/or translated, but not in the 
YAP -/- MEF cell line exposed to virus lacking Cre recombinase (-/- MEF + virus).  
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extreme N-terminus, where hnRNP U binding was shown to occur, and part of the TEAD 
binding site, which was disrupted to the point that TEAD binding would likely no longer 
occur. Although these results and realization that our mouse was not a true null were 
disappointing, we realized that the neomycin resistant gene could still be removed because 
two loxP sites were present on either side of the gene. In the presence of Cre recombinase, 
these loxP sites allow for removal of the intervening genomic sequence and hopefully truly 
disrupt the transcription of the myap transcript. Therefore, to correct the YAP-null 
immortalized MEF cell line, Cre recombinase was subcloned into a retroviral bicistronic 
vector. The resulting retrovirus was used to infect the wild type and YAP-null MEF cell 
lines. These lines were then sorted for GFP+ cells indicating that the cells were infected with 
the virus and stably producing the Cre recombinase. In order to obtain a pure population of 
cells lacking the mutant YAP form (Figure 38C), four cycles of sorting were needed.  
 
Microarray analysis 
From these sorted, YAP-null cells, total RNA was isolated and submitted to the 
NHLBI Microarray Facility, who performed the probing of entire mouse genome 
microrarrays. Thousands of genes were changed between the wild type and YAP-null MEF 
cell lines and analyses of these changes did not point towards the involvement of a single 
signaling cascade. To choose a reasonably sized set of genes to verify the results from the 
microarray analysis by RT-PCR, I screened the list for those genes that could potentially play 
a role in the phenotypes associated with the mouse, frog, or zebrafish embryos lacking YAP. 
In addition, these chosen genes exhibited a range of fold differences and were lower in YAP-
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null cells compared to wild types. Given that YAP is a transcriptional co-activator, the 
rationale was that genes lower in YAP-null cells could be potential gene targets of YAP.  
follistatin-like 3 was chosen because its expression was 85 fold less in the YAP-null 
cells compared to wild type cells. It is structurally and functionally similar to follistatin in 
that they both bind and antagonize the actions of activin and myostatin, both members of the 
TGF-β family (Xia et al., 2009). Overexpression of activin in mice leads to cancer, liver 
necrosis, and cachexia, whereas overexpression of myostatin in mice also leads to cachexia 
as well as reduced muscle and adipocyte mass (Lee, S. J. et al., 2005, Matzuk et al., 1992, 
Matzuk et al., 1994, Reisz-Porszasz et al., 2003, Zimmers et al., 2002). However, mice 
without Follistatin-like 3 exhibited no changes in body weight or muscle composition, but 
instead showed increases in pancreatic islet cell number as well as enhanced glucose 
tolerance and sensitivity to insulin (Mukherjee et al., 2007).  
arhgap22 was chosen because its expression was 42 fold less in the YAP-null cells 
compared to wild type cells. It is a Rho GTPase activating protein (Rho-GAP), which 
associates with a zinc finger transcription factor, Vascular endothelial zinc-finger 1 (Vezf1) 
to inhibit Vezf1 activation of the endothelin-1 promoter, inhibits Rac1 signaling, and 
regulates endothelial cell capillary tube formation (Aitsebaomo et al., 2004).  In addition, 
Arhgap22 plays a role in regulating the transition between mesenchymal or amoeboid 
movements associated with cancerous melanoma cells (Sanz-Moreno et al., 2008). In this 
case, Arhgap22 inactivates Rac through Rho signaling via ROCK, which suppresses 
mesenchymal movements.  
rasGRP3 was chosen because its expression was 26 fold less in the YAP-null cells 
compared to wild type cells. RasGRP3 is a guanine exchange factor (GEF), which facilities 
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the exchange of GDP and GTP and thus promotes active Ras-GTP. Although RasGRP3 
knockout mice exhibited no overt phenotype other than hypogammaglobulinemia, a loss of 
function gene trap for RasGRP3 revealed that RasGRP3 is a VEGF-responsive GEF, which 
important for responses to phorbal esters in endothelial cells (Coughlin et al., 2005, Roberts 
et al., 2004).  
adrenomedullin was chosen because its expression was 25 fold less in the YAP-null 
cells compared to wild type cells. Adrenomedullin is a multifunctional peptide hormone best 
known for its ability to act as a vasodilator, angiogenic factor, regulator of bone metabolism, 
and as tumor growth promoter. Mice lacking Adrenomedullin or its receptor, calcitonin 
receptor-like receptor (Calcrl), did not survive by E14.5 due to cardiovascular defects and 
hydrops fetalis (Caron et al., 2001, Dackor et al., 2006). However, it was noted that reduced 
levels of Adrenomedulin in female heterozygotes resulted in defects in placental 
development resulting in fetal growth restriction (Dackor et al., 2006).  
edg7 was chosen because its expression was 25 fold less in the YAP-null cells 
compared to wild type cells. Edg7 or lysophosphatidic acid (LPA) receptor (LPA3) is a G 
protein-coupled receptor for its ligand, LPA, a lipid-signaling molecule. Deletion of Edg7 
from mice leads to reduced litter sizes due to delayed implantation and altered embryo 
spacing. These defects ultimately resulted in delayed embryonic development, hypertrophic 
placentas, embryos sharing of the placenta, and death by E10.5 (Ye et al., 2005). The delay 
in implantation was likely due to reduced cyclooxygenase-2 (COX-2) levels, which led to 
reduced levels of prostaglandins.   
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Figure 39: RT-PCR validation of microarray results. RT-PCR analysis confirmed that 
follistatin-like3, arhGAP22, adrenomedullin, rasGRP3, edg7, and ephA1 were present in the 
two wild type immortalized MEF cell lines (+/+ MEF A,B), but were missing in the YAP-/- 
MEF cell line.   
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EphA1 was chosen because its expression was 20 fold less in the YAP-null cells 
compared to wild type cells. EphA1 is a receptor for ephrins A1-A6 and is overexpressed in 
breast, liver, lung, and colon carcinomas (Himanen et al., 2007). In general, these receptors 
and ligands are linked to regulating cell activity within the nervous and vascular systems 
through cell-to-cell interactions. Upon ligand binding to the receiving cell, a forward 
signaling cascasde is activated in the receptor-containing cell as well as a reverse signal 
within the ligand-expressing cell.  
RT-PCR analyses revealed that follistatin-like3, arhGAP22, adrenomedullin, 
rasGRP3, edg7, and ephA1 were confirmed to be present in both wild type MEF cell lines 
and absent or dramatically reduced in the YAP-/- MEF cell line (Figure 39). To test whether 
these genes were YAP gene targets, YAP was added back to the YAP-/- MEF cells via 
retroviral integration. Of these genes, adrenomedullin was the only gene that was increased 
in the YAP-/- MEF cells after the addition of exogenous YAP to these cells (Figure 40A). 
Addition of YAP to Jurkat cells, which also lack endogenous YAP expression, increased 
adrenomedullin expression as well (Figure 40B). To test whether YAP could regulate the 
adrenomedullin promoter directly, I subcloned the mouse adrenomedullin promoter (-
2054/+94) from the genomic DNA of NIH-3T3 fibroblast cells into a luciferase reporter. 
Electroporation of the promoter with or without the addition of YAP into the YAP-/- MEF 
cells, showed an increase in promoter activity on the order of two to three fold (Figure 41). In 
addition, maximum expression of YAP occurred at 15 hr after electroporation, while YAP 
expression was gone by 24 hr after electroporation. Although the fold change in 
adrenomedullin promoter activity was only two to three fold, extension of exogenous YAP 
expression might offer larger fold changes in adrenomedullin promoter activity; therefore,
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Figure 40: Adding YAP back to YAP-/- MEFs and Jurkat cells increased 
adrenomedullin expression. RT-PCR analysis showed that the addition of mYAP back to 
the YAP-null MEF cell line (A) and to a T-cell line (Jurkat cells) that lack endogenous YAP 
(B) upregulated adrenomedullin transcription.  
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Figure 41: Time course for mouse adrenomedullin promoter activity in MEF cell lines. 
YAP-/- MEFs were electroporated with the mouse adrenomedullin luciferase and β-gal 
reporter constructs with (+) or without (-) the addition of an expression vector containing 
mYAP. Luciferse and β-gal reporter assays revealed maximum promoter activity at fifteen 
hours, but exogenous YAP expression and adrenomedullin promoter activity was eliminated 
by twenty-four hours. 
 160 
 161 
Figure 42: YAP is present on the mouse adrenomedullin promoter. A) Chromatin isolated 
from the wild type MEF cell line was sheared to sizes between 650 bp and 100 bp. (B) 
Chromatin immunoprecipitations (ChIPs) from sheared wild type MEF chromatin using the 
YAP antibody revealed the presence of YAP at two locations on the adrenomedullin 5’ 
regulatory region, but was not present when a control IgG antibody was used. 
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activation of the adrenomedullin promoter under these conditions suggests that YAP is 
involved in regulating adrenomedullin gene expression. To determine whether endogenous 
YAP was present within this 5’ regulatory region, six primer sets encomposing the 
adrenomedullin promoter (-2054/+94) were used in chromatin immunoprecipitations. ChIP 
analyses revealed that YAP was present endogenously at two locations on the 
adrenomedullin promoter, confirming that adrenomedullin is likely a YAP gene target 
(Figure 42). However, more luciferase assays and in vivo transgenic approaches need to be 
performed to confirm YAP’s transcriptional control over the adrenomedullin gene. 
Chapter V – Summary and Perspectives 
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I provided evidence for YAP playing an important role during early vertebrate 
development by utilizing a series of knockdown and gain-of-function approaches in Xenopus 
laevis and Danio rerio embryos. I found that YAP morpholino (MO)-mediated loss-of-
function prevented further developmental progression at gastrulation, and reduced YAP 
levels resulted in a delay of mesoderm induction. Increasing YAP function expanded the 
neural plate and early neural crest, while concomitantly inhibiting the induction and 
expansion of the preplacodal ectoderm (PPE). In addition, YAP gain-of-function maintained 
and expanded progenitor domains, while inhibiting differentiation. Next, I presented 
preliminary work on the regulation of the yap promoter by Sp1. Finally, I identified 
adrenomedullin as a putative transcriptional target of YAP.  
Although these three diverse projects are interwoven only by their association and 
relevance to understanding the function of YAP in vertebrate development, much time was 
spent contemplating the potential functions of YAP in vivo. Even with the knowledge gained 
from this work and from others, there are still many unanswered questions regarding this 
complicated protein. With that being said, some preliminary data that I collected leads me to 
consider that understanding the role of YAP in vivo revolves around its function as both a 
transcriptional co-activator and a scaffolding protein and that these functions should not be 
separated based on the protein’s localization in the cell. At the beginning of this project, I 
associated YAP’s role as a scaffolding protein with its cytoplasmic location, while its role as 
transcriptional co-activator I associated with its nuclear location. I now believe, however, 
that understanding YAP’s role in vivo involves both functions and that these functions are 
interdependent. More importantly, I believe the scaffolding properties of YAP within the 
nucleus needs further attention and here are several reasons why. 
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According to the current literature, YAP’s interaction with the TEAD family of 
transcription factors clearly has a profound affect on developmental outcomes; however, the 
canonical definition of classifying nuclear proteins as transcription factors or repressors is 
becoming obsolete. We are now moving toward a more realistic view that takes into account 
the clustering of protein complexes present or absent on exposed pieces of chromatin. Not 
only must these clusters of proteins link themselves to one another and to their DNA targets, 
but they must also assist in recruiting chromatin remodeling complexes and the RNA 
polymerase II pre-initiation complex. Although we know a great deal about the cell nucleus, 
we still lack some key pieces of information for understanding the processes of cellular 
differentiation and aging. The nuclear architecture is finally coming into its own as an 
emerging field in cell and developmental biology (Misteli, 2009, Misteli, 2010). There are 
two opposing lines of thought on how the nucleus is organized. One line suggests that the 
architecture of the nucleus is set up and maintained by scaffolding proteins, which link 
structural portions of the nucleus together. The other line suggests that the nuclear 
architecture is a self-organizing entity instructed to regulate internal nuclear processes via 
instructive signals from outside the cell. Although experiments to define which of these two 
opposing lines of thinking are true can be difficult to interpret, I currently prefer to accept the 
possibility that both lines of thinking are true and not mutually exclusive. Furthermore, I 
think that YAP is a good example of how both of these lines of thinking could be true.  
For example, our lab previously identified hnRNP U as a specific binding partner of 
YAP, but not TAZ; however, the functional importance of this interaction was difficult to 
delineate (Howell et al., 2004). This was especially true given that the ascribed functions for 
hnRNP U include regulating pre-RNA processing, mRNA transport, mRNA translation, 
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mRNA stability, and transcription. Furthermore, hnRNP U interacts with RNP particles 
allowing for its association with histone acetylases (HATs), p300, and chromosomal 
attachment regions. The mechanistic details and significance of these interactions are still 
being worked out. hnRNP U can be divided into three main interacting protein pieces. The 
amino terminus of hnRNP U interacts with DNA, the middle interacts with the 
phosphorylated C terminal domain (CTD) of RNA polymerase II, and the carboxy terminus 
interacts with nuclear actin and mRNA (Kukalev et al., 2005). Although this hnRNP U-YAP 
interaction was thoroughly analyzed and published, I repeated the co-immunoprecipitations 
both ways and found that the interaction was quite robust (not shown). Given these 
reassuring results of YAP’s interaction with hnRNP U, I was curious as to which portion of 
hnRNP U YAP interacted. Afterall, where YAP binds to hnRNP U could potentially compete 
with other potential interactions and affect the function of hnRNP U. In addition, further 
support for the putative importance of YAP’s interaction with hnRNP U came from the 
hnRNP U hypomorph, which clearly exhibited a delay in development and thus was similar 
to the in vivo results we observed in the mouse, frog, and zebrafish (Roshon et al., 2005). 
Because of these anecdotal observations, I decided to perform a GST pulldown with the 
proline-rich N-terminus of YAP and [35S] radiolabeled portions of hnRNP U. I found that 
YAP bound specifically to the carboxy terminus of hnRNP U (Figure 43), which is shown to 
also interact with nuclear actin and mRNA. However, I did not further pursue the details 
regarding the functional outcome of such an interaction, yet I feel that it may be worth 
pursuing in the future (Kukalev et al., 2005).  
Another example of YAP’s putative role in the nuclear architecture came from my 
literature searches for evidence of phenotypes similar to those I observed in my YAP
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Figure 43: YAP binds to the C-terminus of hnRNP U. Three different portions (N-
terminus (1-250), middle (251-550), and the C-terminus (551-823)) of hnRNP U were in 
vitro translated in the presence of  [35S] radio-labeled methionine. GST pulldowns using 
purified GST, GST-YAP-PR (proline rich N-terminus) proteins, and the three different 
portions of hnRNP U showed that the C-terminus of hnRNP U strongly binds to the proline 
rich N-terminus of YAP.  
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morphant or mutant Xenopus laevis embryos. I serendipitously came across a paper whereby 
loss of Brg1, the catalytic subunit of the SWI/SNF chromatin remodeling complex, resulted 
in expansion of sox2+ neural progenitors and loss of neural differentiation as evidence by 
reduced n-tubulin in situ staining (Seo et al., 2005). This paper was of particular interest 
because we were previously contacted by Dr. Bernard Weissman (UNC) regarding the 
possibility that YAP may bind to another member of the SWI/SNF chromatin remodeling 
complex, BAF155. We provided Dr. Weissman with some of our purified YAP antibody, but 
never heard the outcome of their co-immunoprecipitation experiments. However, given these 
two pieces of anecdotal information, I looked at the proteins to see if Brg1 and/or BAF155 
contained a PPxY motif, which would allow their binding to the WW domains of YAP. In 
fact, both Brg1 and BAF155 possess PPxY motifs and bound to the WW domain of YAP in 
GST pulldowns using endogenous HeLa cell lysates (Figure 44). Endogenous co-
immunoprecipitations were more difficult and could not be confirmed. However, I obtained 
an hBrg1construct from Dr. Keji Zhao and co-expressed HA-Brg1 and Myc-mYAP in HeLa 
cells. By immunoprecipitating HA-Brg1 from isolated nuclear extracts, I obtained a modest 
amount of YAP binding from the resulting co-immunoprecipitations (Figure 45). Based on 
these results, I conclude that YAP is capable of binding to the SWI/SNF chromatin-
remodeling complex; however, I was unable to define the functional importance of such an 
interaction.    
I believe these interactions further support the hypothesis that YAP is more than just a 
transcriptional co-activator that associates with TEAD transcription factors to activate target 
genes. I hypothesize that YAP plays a more prominent role in regulating the fundamental 
interworkings of the nucleus through its interaction with other nuclear proteins and protein 
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Figure 44: BAF155 and Brg1 can bind to the YAP WW1 domain. Western blot analyses 
of GST pulldowns using purified GST, GST-YAP-WW1, and nuclear lysates from HeLa 
cells showed that both BAF155 and Brg1 could bind to the WW1 domain of YAP, but not to 
GST.  
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Figure 45: Co-immunoprecipitation of YAP with Brg1. HA-Brg1 and Myc-mYAP-cAct, 
the constitutively active, nuclear form of YAP, were co-transfected into HeLa cells. 
Immunoprecipitations using beads conjugated with an HA antibody and subsequent western 
blot analyses using a HA antibody showed that HA-Brg1 was immunoprecipitated and a 
YAP antibody illustrated that YAP co-immunoprecipitated with Brg1. 
 174 
 
 
 
 175 
complexes than is currently appreciated. Not only do these preliminary data suggest a 
possible role in linking nuclear pieces together for a common goal, but my functional 
analyses of YAP deletions reveal that the PDZ-binding motif may play a role in regulating 
muscle and epidermal differentiation. Although an affinity peptide pulldown with whole 
Xenopus laevis lysates and the PDZ-binding motif of YAP was previously performed, the 
experimental outcome was extremely dirty; therefore, such an experiment deserves revisiting 
in light of these current findings. 
Finally, I would like to briefly point out an evolutionary perspective on the presence 
and function of YAP and TAZ, especially given how important YAP appears to be for proper 
vertebrate development. By constructing a phylogenetic tree for YAP and TAZ, I was able to 
find a YAP and TAZ homolog for most every vertebrate, illustrating that there was a clear 
duplication event that occurred between the invertebrate and vertebrate branches on this 
phylogenetic tree (Figure 46). Invertebrates only have a single YAP/TAZ protein, which is 
actually more similar to YAP than TAZ as they have two WW domains. Surprisingly, all the 
invertebrate YAP/TAZ homologs contained the traditional PDZ-binding motif at its C-
terminus. I say this was surprising because the fly homolog, Yorkie, does not have this 
conserved domain. Therefore, some functional data obtained from the fly may not be 
conserved in the rest of the animal kingdom. However, what I found most interesting is that 
the conserved signaling pathway, the Hippo signaling pathway, of which YAP is a part, and 
its components, are conserved all the way down to the base of the evolutionary tree. These 
members are first present in the placozoan, Trichoplax adhaerens (Srivastava et al., 2008). 
The simplicity of this organism is astounding. It is only one millimeter thick, is made of only 
three layers, and feeds on microbes by absorption on their underside. In addition, these
 176 
Figure 46: Evolutionary conservation of YAP and TAZ. A phylogenetic tree for YAP and 
TAZ was constructed using MEGA 4.1. Although all vertebrate homologs of YAP and TAZ 
are not listed on this tree, a homolog could be found for every vertebrate tested; however, 
only one YAP/TAZ homolog could be found in the genomes of the listed invertebrates, 
suggesting that the prescence of TAZ in vertebrates is the result of a duplication event that 
occurred between the invertebrate and vertebrate branches. 
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organisms reproduce asexually although there is some scant data suggesting they may have 
evolved some primitive sexual reproduction. Notably, sponge and hydra did not contain 
components of the conserved Hippo signaling pathway (Chapman et al., 2010, Srivastava et 
al., 2010). This observation makes one wonder how those organisms survive without this 
pathway, yet almost all other organisms possesses such a pathway. Furthermore, given the 
complexity of YAP’s diverse and overlapping function with other signaling pathways in 
vertebrates, it may be useful to study its earliest, most fundamental cellular function in 
Trichoplax adhaerens. 
In summary, I characterized the effects of YAP loss-of-function and gain-of-function 
approaches in Xenopus laevis and Danio rerio embryos. YAP morpholino (MO)-mediated 
loss-of-function resulted in a delay of mesoderm induction and impaired axis formation, 
similar to the mouse phenotype. YAP gain-of-function in Xenopus laevis expanded the 
progenitor populations in the neural plate and neural plate border zone, while concomitantly 
inhibiting markers for the neural crest, preplacodal ectoderm, hatching gland, epidermis, and 
somitic muscle. I found that yap expression is controlled by a TATA-less promoter, which 
includes a GC box where Sp1 binds and regulates yap transcription. I also found that 
adrenomedullin, a multifunctional peptide hormone known to act as a vasodilator, angiogenic 
factor, regulator of placental development, and tumor growth promoter, is a newly identified, 
putative target of YAP. These studies demonstrate that YAP is involved in the process of cell 
differentiation and the lack or overabundance of YAP protein disrupts the developmental 
time line of vertebrates with grievous consequences. Understanding the mechanistic details 
of these effects involve understanding the transcriptional control of YAP and its target genes. 
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In the future, understanding the linkage between YAP, the nuclear architecture, and 
transcriptional regulation will bolster our understanding of cell differentiation. 
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